[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 200
1. Kuroda N, Tanida N, Ohara M, Hirouchi T, Mizuno K, Kubo A, Lee GH: Anal canal adenocarcinoma with MUC5AC expression suggestive of anal gland origin. Med Mol Morphol; 2007 Mar;40(1):50-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal adenocarcinoma with MUC5AC expression suggestive of anal gland origin.
  • Anal canal adenocarcinomas arising in the anal ducts or glands are very rare neoplasms, and few useful immunohistochemical markers of these carcinomas are known to date.
  • A 57-year-old man presented with anal bleeding, difficulty of defecation, and anal pain.
  • Macroscopic findings of the surgically resected material showed circular stenosis of the anal canal.
  • Immunohistochemically, normal rectal-type mucosa and normal anal ducts/glands showed the patterns of cytokeratin 7 (CK7)(-)/CK19(+, focal)/MUC5AC(-) and CK7(+, diffuse)/CK19(+, diffuse)/MUC5AC(+, focal), respectively, and neoplastic cells showed the pattern of CK7(+, diffuse)/CK19(+, diffuse)/MUC5AC(+, focal).
  • Finally, our preliminary report suggests that the immunohistochemical combination of CK7, CK19, and MUC5AC may be an available marker for adenocarcinoma of anal ducts/glands origin.
  • [MeSH-major] Adenocarcinoma / pathology. Anal Canal / pathology. Anus Neoplasms / pathology. Mucins / metabolism

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1996 Dec;49(12):1009-11 [9038740.001]
  • [Cites] Br J Surg. 1970 Jun;57(6):434-6 [4317275.001]
  • [Cites] Dis Colon Rectum. 1993 Apr;36(4):383-7 [8458266.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):268-72 [3359895.001]
  • [Cites] Histochem J. 1981 Nov;13(6):921-30 [7338481.001]
  • [Cites] Histopathology. 1995 Jan;26(1):39-44 [7536178.001]
  • [Cites] Dis Colon Rectum. 1976 Nov-Dec;19(8):694-701 [186242.001]
  • [Cites] Arch Pathol Lab Med. 2001 Aug;125(8):1074-7 [11473461.001]
  • [Cites] J Am Osteopath Assoc. 2001 Aug;101(8):450-3 [11526879.001]
  • (PMID = 17384991.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins
  •  go-up   go-down


2. Obaidat NA, Awamleh AA, Ghazarian DM: Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region. Eur J Dermatol; 2006 Sep-Oct;16(5):576-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region.
  • We report the case of a 67-year-old woman who presented with a peri-anal skin tag.
  • Similar to vulvar lesions, peri-anal apocrine tumours are believed to arise in mammary like glands (MLGs).
  • To the best of our knowledge, this is the first description of a peri-anal adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101482.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


3. Carpenter JB, Rennels MA: Immunophenotypic characteristics of anal gland carcinoma. Arch Pathol Lab Med; 2008 Oct;132(10):1547-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic characteristics of anal gland carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Anus Neoplasms / metabolism. Keratin-5 / metabolism. Keratin-6 / metabolism. Membrane Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Arch Pathol Lab Med. 2007 Aug;131(8):1304-11 [17683193.001]
  • (PMID = 18834205.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / Keratin-7; 0 / Membrane Proteins
  •  go-up   go-down


Advertisement
4. Huang ZM, Li HZ, Xiao H, Ji ZG: [Melanoma adrenal metastasis: report of 3 cases and literature review]. Zhonghua Yi Xue Za Zhi; 2010 Apr 27;90(16):1123-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two cases had a history of cutaneous melanoma and another one suffered previously from anal melanoma.
  • The disease-free interval to adrenal metastasis were 25, 37, 33 months respectively.
  • One received adrenalectomy via retroperitoneal laparoscopic approach while another patient with tumor thrombus in inferior vena cava underwent right adrenalectomy and extraction of tumor thrombus out of inferior vena cava in traditional open surgery.
  • CONCLUSION: Melanoma metastasis to adrenal gland is rare and it generally has a poor prognosis.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646432.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 8
  •  go-up   go-down


5. Schairer C, McCarty CA, Isaacs C, Sue LY, Pollak MN, Berg CD, Ziegler RG: Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort. Horm Cancer; 2010 Apr;1(2):100-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early prospective studies suggested circulating insulin-like growth factor (IGF)-I was positively associated with risk of premenopausal, but not postmenopausal, breast cancer; however, a recent, large analysis reported a statistically significant positive association with postmenopausal disease.
  • [MeSH-major] Breast Neoplasms / blood. Insulin-Like Growth Factor Binding Protein 3 / blood. Insulin-Like Growth Factor I / metabolism


6. Jansen SA, Paunesku T, Fan X, Woloschak GE, Vogt S, Conzen SD, Krausz T, Newstead GM, Karczmar GS: Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model. Radiology; 2009 Nov;253(2):399-406
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To combine dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging with x-ray fluorescence microscopy (XFM) of mammary gland tissue samples from mice to identify the spatial distribution of gadolinium after intravenous injection.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • [Cites] Biometals. 2009 Feb;22(1):197-205 [19130257.001]
  • [Cites] Scanning Microsc. 1992 Dec;6(4):1137-43; discussion 1143-5 [1295083.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11236-40 [7972041.001]
  • [Cites] Radiology. 1995 Sep;196(3):593-610 [7644617.001]
  • [Cites] J Comput Assist Tomogr. 1996 Jan-Feb;20(1):9-14 [8576489.001]
  • [Cites] Radiology. 1997 Feb;202(2):413-20 [9015067.001]
  • [Cites] Radiology. 1997 Apr;203(1):137-44 [9122382.001]
  • [Cites] Radiology. 1998 Jun;207(3):675-81 [9609890.001]
  • [Cites] J Magn Reson Imaging. 1998 Sep-Oct;8(5):1126-34 [9786152.001]
  • [Cites] Med Image Anal. 2005 Aug;9(4):315-29 [15950895.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):387-98 [15949236.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):708-18 [15971199.001]
  • [Cites] Magn Reson Imaging. 2005 Jul;23(6):733-8 [16198828.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):379-81 [16297079.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):382-90 [16297080.001]
  • [Cites] JBR-BTR. 2005 Sep-Oct;88(5):225-32 [16302331.001]
  • [Cites] J Magn Reson Imaging. 2006 Sep;24(3):646-56 [16878308.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4603-10 [17008702.001]
  • [Cites] J Magn Reson Imaging. 2006 Nov;24(5):1140-7 [17024660.001]
  • [Cites] Phys Med Biol. 2006 Dec 21;51(24):N451-9 [17148815.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89 [17392385.001]
  • [Cites] Lancet. 2007 Aug 11;370(9586):485-92 [17693177.001]
  • [Cites] Radiology. 2007 Dec;245(3):684-91 [18024450.001]
  • [Cites] J Am Chem Soc. 2007 Dec 26;129(51):15760-1 [18047347.001]
  • [Cites] Nanomedicine. 2008 Sep;4(3):201-7 [18567541.001]
  • [Cites] Eur Radiol. 2008 Oct;18(10):2164-73 [18545998.001]
  • [Cites] Phys Med Biol. 2008 Oct 7;53(19):5481-93 [18780960.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17943-8 [19004780.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1020-7 [10713685.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4272-7 [11358855.001]
  • [Cites] Br J Radiol. 2003 Jan;76(901):3-12 [12595319.001]
  • [CommentIn] Radiology. 2009 Nov;253(2):281-3 [19864520.001]
  • (PMID = 19864527.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / 1 R01 EB003108-04; United States / NCI NIH HHS / CA / R21 CA104774; United States / NCI NIH HHS / CA / R21 CA104774-01A2; United States / NIBIB NIH HHS / EB / R01 EB003108; United States / NIBIB NIH HHS / EB / R01 EB002100
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  • [Other-IDs] NLM/ PMC2770112
  •  go-up   go-down


7. Król M, Polańska J, Pawłowski KM, Turowski P, Skierski J, Majewska A, Ugorski M, Morty RE, Motyl T: Transcriptomic signature of cell lines isolated from canine mammary adenocarcinoma metastases to lungs. J Appl Genet; 2010;51(1):37-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastasis is a final step in the progression of mammary gland cancer, usually leading to death.
  • Two adenocarcinoma cell lines isolated from the canine mammary gland (CMT-W1 and CMT-W2) were compared with cell lines isolated from their lung metastases (CMT-W1M and CMT-W2M) with regards to the following cytometric parameters: cell cycle, ploidy, Bcl-2 expression, susceptibility to induced apoptosis, and transcriptomic profile.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Gene Expression Profiling. Lung Neoplasms / genetics. Mammary Neoplasms, Animal / genetics
  • [MeSH-minor] Animals. Apoptosis. Blotting, Western. Dogs. Female. Fluorescent Antibody Technique. Oligonucleotide Array Sequence Analysis. Ploidies. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):839-50 [16322325.001]
  • [Cites] Mol Biol Cell. 2008 Jan;19(1):248-61 [17989364.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6176-8 [2400984.001]
  • [Cites] Cell. 2003 Jun 27;113(7):821-3 [12837240.001]
  • [Cites] J Physiol Pharmacol. 2009 May;60 Suppl 1:73-84 [19609016.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 [14665696.001]
  • [Cites] Vet Pathol. 2006 Nov;43(6):934-42 [17099150.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3143-9 [3211140.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2028-34 [7738169.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6672-6 [15221014.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] J Endocrinol. 2002 Apr;173(1):161-7 [11927395.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6278-88 [12414658.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Anim Genet. 2008 Aug;39(4):333-45 [18462483.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Mar 10;288(6419):749-51 [6423061.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 19;309(2):464-8 [12951072.001]
  • [Cites] Genome Biol. 2007;8(1):R2 [17204140.001]
  • [Cites] Nat New Biol. 1973 Apr 4;242(118):148-9 [4512654.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3497-508 [15867337.001]
  • [Cites] Anal Biochem. 2006 Sep 1;356(1):36-43 [16844072.001]
  • [Cites] J Physiol Pharmacol. 2009 May;60 Suppl 1:95-106 [19609018.001]
  • [Cites] Nat Genet. 2003 May;34(1):23; author reply 25 [12721548.001]
  • [Cites] J Natl Cancer Inst. 1968 Feb;40(2):295-305 [5694271.001]
  • [Cites] Mamm Genome. 2007 Sep;18(9):617-26 [17726633.001]
  • [Cites] Cancer Metastasis Rev. 1990 Sep;9(2):125-36 [2253312.001]
  • [Cites] Int J Oncol. 2008 Jul;33(1):69-79 [18575752.001]
  • [Cites] Mol Cancer Ther. 2004 Feb;3(2):161-8 [14985456.001]
  • [Cites] Mol Cancer Res. 2003 May;1(7):485-99 [12754296.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D284-8 [15608197.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Physiol Pharmacol. 2009 May;60 Suppl 1:85-94 [19609017.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2541-6 [10811137.001]
  • (PMID = 20145299.001).
  • [ISSN] 1234-1983
  • [Journal-full-title] Journal of applied genetics
  • [ISO-abbreviation] J. Appl. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


8. Bullitt E, Wolthusen PA, Brubaker L, Lin W, Zeng D, Van Dyke T: Malignancy-associated vessel tortuosity: a computer-assisted, MR angiographic study of choroid plexus carcinoma in genetically engineered mice. AJNR Am J Neuroradiol; 2006 Mar;27(3):612-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: The ability to assess tumor malignancy and monitor treatment response noninvasively would be of value to both clinicians and animal investigators.
  • This report describes the MR imaging characteristics of a genetically engineered mouse model of choroid plexus carcinoma (CPC) during tumor growth and progression to malignancy.
  • Malignancy assessment was based upon a statistical analysis of vessel tortuosity, by using an equation derived from an earlier study of human brain tumor patients.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1994 Aug 26;78(4):703-11 [8069917.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1969 Apr;105(4):795-805 [4308528.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):585-90 [15560716.001]
  • [Cites] Med Image Anal. 2005 Feb;9(1):39-49 [15581811.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8218-23 [16166297.001]
  • [Cites] Acad Radiol. 2005 Oct;12(10):1232-40 [16179200.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):94-5 [10639502.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Feb;14(1):31-6 [10850285.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Neuroradiology. 2001 May;43(5):345-52 [11396737.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):6017-30 [11486039.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2186-9 [11691952.001]
  • [Cites] Cell. 2002 Jan 25;108(2):135-44 [11832204.001]
  • [Cites] Int J Mol Med. 2002 Mar;9(3):299-310 [11836637.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Feb;21(2):61-75 [11929106.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1284-91 [11948144.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):783-9 [12185064.001]
  • [Cites] J Neuroradiol. 2002 Jun;29(2):105-13 [12297732.001]
  • [Cites] Neuroradiology. 2003 Apr;45(4):205-11 [12687302.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71 [12956271.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):421-37 [14973386.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):577-84 [15560715.001]
  • (PMID = 16552004.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NIBIB NIH HHS / EB / R01 EB000219-08A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS53783; NLM/ PMC2504702
  •  go-up   go-down


9. Mellanby RJ, Craig R, Evans H, Herrtage ME: Plasma concentrations of parathyroid hormone-related protein in dogs with potential disorders of calcium metabolism. Vet Rec; 2006 Dec 16;159(25):833-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The plasma concentrations of total calcium, ionised calcium, albumin, parathyroid hormone and parathyroid hormone-related protein (PTHrp) were measured in 25 dogs with lymphoma, nine dogs with primary hyperparathyroidism and seven dogs with adenocarcinoma of the apocrine gland of the anal sac.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / veterinary. Anal Sacs. Animals. Case-Control Studies. Dogs. Hyperparathyroidism / diagnosis. Hyperparathyroidism / veterinary. Lymphoma / diagnosis. Lymphoma / veterinary. Predictive Value of Tests. Sensitivity and Specificity. Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / veterinary

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172477.001).
  • [ISSN] 0042-4900
  • [Journal-full-title] The Veterinary record
  • [ISO-abbreviation] Vet. Rec.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


10. Kim HJ, Chung JK, Hwang DW, Lee DS, Kim S: In vivo imaging of miR-221 biogenesis in papillary thyroid carcinoma. Mol Imaging Biol; 2009 Mar-Apr;11(2):71-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Diagnostic Imaging / methods. Luciferases / metabolism. MicroRNAs / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Line. Cell Line, Tumor. Cytomegalovirus / genetics. Cytomegalovirus / metabolism. Gene Expression Profiling. Genes, Reporter. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Polymerase Chain Reaction. Thyroid Gland / metabolism. Whole Body Imaging / methods

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Sci. 2006 Aug;101(4):267-70 [16921236.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9779-84 [12902540.001]
  • [Cites] Cell Cycle. 2007 Aug 15;6(16):2005-9 [17721077.001]
  • [Cites] Gene Ther. 2006 Mar;13(6):496-502 [16195701.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):2-12 [17028302.001]
  • [Cites] Bioconjug Chem. 2004 Nov-Dec;15(6):1376-88 [15546205.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:175-205 [17506695.001]
  • [Cites] Dev Cell. 2006 Oct;11(4):441-50 [17011485.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 May;6(5):376-85 [15852042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18081-6 [16330772.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Anal Biochem. 1988 Nov 15;175(1):5-13 [3072883.001]
  • [Cites] Nature. 2000 Feb 24;403(6772):901-6 [10706289.001]
  • [Cites] J Nucl Med. 2008 Feb;49(2):285-94 [18199619.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Cell. 2003 Apr 4;113(1):25-36 [12679032.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] RNA. 2006 Jul;12(7):1161-7 [16738409.001]
  • [Cites] Biotechniques. 1989 Nov-Dec;7(10):1116-22 [2698191.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):497-508 [16728577.001]
  • [Cites] Dev Biol. 2007 Feb 1;302(1):1-12 [16989803.001]
  • [Cites] Mol Cell Endocrinol. 2006 Feb 26;246(1-2):69-75 [16388894.001]
  • [Cites] Mol Ther. 2005 Mar;11(3):435-43 [15727940.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1600-8 [18270258.001]
  • [Cites] Genes Dev. 2006 Mar 1;20(5):515-24 [16510870.001]
  • (PMID = 19030936.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN221 microRNA, human; 0 / MicroRNAs; EC 1.13.12.- / Luciferases
  •  go-up   go-down


11. Nakata M, Miwa Y, Nakayama H, Sakai T, Sasaki N: Localised radiotherapy for a ferret with possible anal sac apocrine adenocarcinoma. J Small Anim Pract; 2008 Sep;49(9):476-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localised radiotherapy for a ferret with possible anal sac apocrine adenocarcinoma.
  • A seven-year-old, neutered male ferret was referred to our hospital with two perianal masses (2.4x3.0 and 2.4x3.5 cm, respectively) that had recurred after initial surgical excision.
  • On histopathology, the masses were diagnosed as apocrine adenocarcinoma possibly of anal gland origin based on tumour location.
  • Cytology of a sample of the pleural effusion suggested mesothelioma, and no obvious pulmonary metastasis of anal sac adenocarcinoma were identified on thoracic radiography.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Gland Neoplasms / radiotherapy. Anal Sacs. Ferrets
  • [MeSH-minor] Animals. Fatal Outcome. Male. Mesothelioma / radiography. Mesothelioma / surgery. Mesothelioma / veterinary. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / surgery. Neoplasm Recurrence, Local / veterinary. Neoplasms, Second Primary / radiography. Neoplasms, Second Primary / surgery. Neoplasms, Second Primary / veterinary. Pleural Effusion / etiology. Pleural Effusion / radiography. Pleural Effusion / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18631226.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Sierra Montenegro E, Sierra Luzuriaga G, Leone Stay G, Salazar Menéndez V, Quiñonez Auria C: Perianal nodular hidradenocarcinoma. Case report. Cir Cir; 2010 Mar-Apr;78(2):173-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal nodular hidradenocarcinoma. Case report.
  • Nodular hidradenocarcinoma (NH) is a rare malignant and aggressive tumor of the eccrine glands.
  • The objective of this study is to report a case of perianal hidradenocarcinoma.
  • Physical examination revealed a small perianal tumor that was palpated near the anal canal.
  • Pathology report revealed perianal hidradenoma.
  • Extensive resection of the tumor was done.
  • CONCLUSIONS: In patients with a first symptom of metastases in the inguinal region, suspicion must be directed to the anal canal.
  • [MeSH-major] Eccrine Glands. Sweat Gland Neoplasms
  • [MeSH-minor] Aged. Anal Canal. Female. Humans

  • Genetic Alliance. consumer health - Hidradenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20478121.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


13. Aguirre-Hernández J, Polton G, Kennedy LJ, Sargan DR: Association between anal sac gland carcinoma and dog leukocyte antigen-DQB1 in the English Cocker Spaniel. Tissue Antigens; 2010 Dec;76(6):476-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between anal sac gland carcinoma and dog leukocyte antigen-DQB1 in the English Cocker Spaniel.
  • Anal sac gland carcinomas occur frequently in English Cocker Spaniels and, to a lesser extent, in other spaniel breeds.
  • The disease typically presents in dogs aged 8 years or older and frequently metastasises to the local lymph nodes.
  • The association between anal sac gland carcinoma in English Cocker Spaniels and the major histocompatibility complex class II loci (the dog leukocyte antigen loci DLA-DRB1, -DQA1, -DQB1) was investigated in 42 cases and 75 controls.
  • This is the second disease in English Cocker Spaniels for which the most common DLA-DQB1 allele in the breed has been shown to have a higher frequency in cases than controls, while the second most common allele in the breed (*02001) has a significantly higher frequency in the controls, compared with the cases.
  • [MeSH-major] Dog Diseases / immunology. Gene Frequency / immunology. Histocompatibility Antigens Class I / immunology. Histocompatibility Antigens Class II / immunology. Neoplasms / immunology. Neoplasms / veterinary

  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 20727114.001).
  • [ISSN] 1399-0039
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / Histocompatibility Antigens Class II
  •  go-up   go-down


14. Liu GY, Luo Q, Xiong B, Pan C, Yin P, Liao HF, Zhuang WC, Gao HZ: Tissue array for Tp53, C-myc, CCND1 gene over-expression in different tumors. World J Gastroenterol; 2008 Dec 21;14(47):7199-207
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tissue array included 120 points of esophagus, 120 points of stomach, 80 points of rectum, 60 points of thyroid gland, 100 points of mammary gland, 80 points of liver, and 80 points of colon.
  • The expression level of C-myc gene was different in esophagus carcinoma tissue samples (chi2 = 18.495, P = 0.000), stomach carcinoma tissue samples (chi2 = 23.750, P = 0.000), and thyroid gland tissue samples (chi2 = 10.999, P = 0.004).
  • [MeSH-major] Cyclin D1 / metabolism. Esophageal Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Proto-Oncogene Proteins c-myc / metabolism. Stomach Neoplasms / metabolism. Tissue Array Analysis. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Breast Neoplasms / ethnology. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. China. Colonic Neoplasms / ethnology. Colonic Neoplasms / genetics. Colonic Neoplasms / metabolism. Humans. Liver Neoplasms / ethnology. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. RNA, Messenger / metabolism. Rectal Neoplasms / ethnology. Rectal Neoplasms / genetics. Rectal Neoplasms / metabolism. Thyroid Neoplasms / ethnology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 May 1;57(9):1769-75 [9135021.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):207-18 [11679179.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jul;74(1):25-31 [12150449.001]
  • [Cites] Mol Cell Biol. 1984 Feb;4(2):276-81 [6366518.001]
  • [Cites] Lab Invest. 1986 Aug;55(2):244-8 [3525985.001]
  • [Cites] Mol Cell Biol. 1985 Oct;5(10):2851-5 [3915536.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8403-7 [2236048.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5006-10 [2052583.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8237-41 [1896475.001]
  • [Cites] Am J Pathol. 1992 Sep;141(3):545-50 [1519662.001]
  • [Cites] Anal Biochem. 1993 Nov 15;215(1):86-9 [7507651.001]
  • [Cites] Am J Clin Pathol. 1994 Nov;102(5):695-8 [7942638.001]
  • [Cites] J Cell Biochem Suppl. 1996;25:23-8 [9027594.001]
  • [Cites] Cell. 1997 Feb 7;88(3):405-15 [9039267.001]
  • [Cites] J Pathol. 1997 Mar;181(3):267-9 [9155710.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 May;123(5):497-502 [9158396.001]
  • [Cites] Br J Cancer. 1997;76(1):21-8 [9218727.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Br J Plast Surg. 1998 Apr;51(3):191-4 [9664877.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):259-62 [15668280.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):637-46 [15612024.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nat Methods. 2006 Jan;3(1):27-9 [16369549.001]
  • [Cites] RNA. 2006 May;12(5):913-20 [16540696.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):661-5 [17251932.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1688-95 [11104567.001]
  • (PMID = 19084934.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  • [Other-IDs] NLM/ PMC2776877
  •  go-up   go-down


15. Pasini B, Stratakis CA: SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med; 2009 Jul;266(1):19-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Beside the well-known syndromes associated with an increased risk of adrenal phaeochromocytoma, Von Hippel Lindau disease, multiple endocrine neoplasia type 2 and neurofibromatosis type 1, the study of inherited predisposition to head and neck paragangliomas led to the discovery of the novel 'paraganglioma-phaeochromocytoma syndrome' caused by germline mutations in three genes encoding subunits of the succinate dehydrogenase (SDH) enzyme (SDHB, SDHC and SDHD) thus opening an unexpected connection between mitochondrial tumour suppressor genes and neural crest-derived cancers.
  • The disease is characterized by autosomal dominant inheritance with a peculiar parent-of-origin effect for SDHD mutations.

  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • University of Turin Instituional Repository AperTO. Full Text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2127-30 [15623805.001]
  • [Cites] JAMA. 2005 Oct 26;294(16):2057-63 [16249420.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9651-8 [16266984.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8812-8 [16314641.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1011-6 [16322339.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):213-9 [16258955.001]
  • [Cites] BMC Med Genet. 2005;6:39 [16288654.001]
  • [Cites] BMC Med Genet. 2006;7:1 [16405730.001]
  • [Cites] Intern Med J. 2006 Feb;36(2):129-31 [16472267.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):827-36 [16317055.001]
  • [Cites] Ann Clin Biochem. 2006 Mar;43(Pt 2):156-60 [16536919.001]
  • [Cites] J Endocrinol Invest. 2006 Apr;29(4):350-2 [16699302.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Aug;91(8):3071-5 [16757530.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):763-4 [16916404.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):785-9 [16304664.001]
  • [Cites] Am J Med Genet A. 2006 Nov 15;140(22):2441-6 [17041923.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4505-9 [16912137.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:138-48 [17102080.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2008 May;265(5):557-63 [17987308.001]
  • [Cites] An Pediatr (Barc). 2008 May;68(5):527-9 [18448004.001]
  • [Cites] Endocr Pract. 2008 Apr;14(3):340-6 [18463041.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1609-15 [18211978.001]
  • [Cites] Endocr J. 2008 May;55(2):299-303 [18362451.001]
  • [Cites] Diagn Mol Pathol. 2008 Jun;17(2):94-100 [18382370.001]
  • [Cites] J Hypertens. 2008 Jul;26(7):1395-401 [18551016.001]
  • [Cites] Head Neck. 2008 Jul;30(7):964-9 [18213727.001]
  • [Cites] Anal Quant Cytol Histol. 2008 Apr;30(2):119-23 [18561749.001]
  • [Cites] Am J Hum Genet. 2008 Aug;83(2):261-8 [18678321.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Dec;92(12):4853-64 [17848412.001]
  • [Cites] Eur J Hum Genet. 2008 Jan;16(1):79-88 [17667967.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2008 Feb;4(2):111-5 [18212813.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Apr;68(4):561-6 [17973943.001]
  • [Cites] Genes Dev. 2008 Apr 1;22(7):884-93 [18334619.001]
  • [Cites] J Med Genet. 2008 Apr;45(4):233-8 [18057081.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6822-5 [11156372.001]
  • [Cites] Lancet. 2001 Apr 14;357(9263):1181-2 [11323050.001]
  • [Cites] Am J Med Genet. 2001 May 15;100(4):311-4 [11343322.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):255-63 [11391796.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):274-81 [11391798.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1937-42 [11395368.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2890-4 [11397905.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):49-54 [11404820.001]
  • [Cites] Am J Med Genet. 2001 Jan 1;98(1):32-6 [11426453.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):5084-6 [11526495.001]
  • [Cites] Am J Hum Genet. 2001 Dec;69(6):1186-97 [11605159.001]
  • [Cites] Laryngoscope. 2001 Oct;111(10):1822-7 [11801952.001]
  • [Cites] Biochim Biophys Acta. 2002 Jan 17;1553(1-2):140-57 [11803023.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1117-22 [11850829.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):875-7 [11857371.001]
  • [Cites] J Med Genet. 2002 Mar;39(3):178-83 [11897817.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jul;34(3):325-32 [12007193.001]
  • [Cites] Eur J Hum Genet. 2002 Aug;10(8):457-61 [12111639.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2061-6 [12114404.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4101-5 [12213855.001]
  • [Cites] Otol Neurotol. 2002 Sep;23(5):755-9 [12218630.001]
  • [Cites] Mol Aspects Med. 2002 Oct;23(5):369-84 [12231007.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2347-54 [12351569.001]
  • [Cites] J Med Genet. 2002 Oct;39(10):E64 [12362046.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4771-4 [12364472.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 3;100(17):1260-2 [18728283.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Oct;69(4):587-96 [18419787.001]
  • [Cites] Hum Genet. 2008 Oct;124(3):279-85 [18726616.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2008 Nov;36(5):517-9 [18692411.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Dec;69(6):906-10 [18681855.001]
  • [Cites] Oncogene. 2002 Oct 24;21(49):7605-8 [12386824.001]
  • [Cites] Head Neck. 2003 Feb;25(2):146-51 [12509798.001]
  • [Cites] Science. 2003 Jan 31;299(5607):700-4 [12560550.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1358-64 [12618761.001]
  • [Cites] Hum Genet. 2003 Jul;113(1):92-4 [12658451.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):1055-8 [12782822.001]
  • [Cites] J Med Genet. 2003 Jun;40(6):e75 [12807974.001]
  • [Cites] Lancet. 1989 Dec 2;2(8675):1291-4 [2574254.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Apr;102(4):382-90 [2113266.001]
  • [Cites] Hum Mol Genet. 1992 Apr;1(1):7-10 [1301144.001]
  • [Cites] Hum Genet. 1993 May;91(4):357-61 [8388849.001]
  • [Cites] Hum Genet. 1995 Jan;95(1):56-62 [7814027.001]
  • [Cites] Eur J Hum Genet. 1994;2(3):148-58 [7834274.001]
  • [Cites] Nat Genet. 1995 Oct;11(2):144-9 [7550341.001]
  • [Cites] Am J Hum Genet. 1997 Jan;60(1):121-32 [8981955.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jun;82(6):1766-71 [9177379.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2559-65 [9253334.001]
  • [Cites] Am J Med Genet. 1997 Oct 3;72(1):66-70 [9295078.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):755-64; discussion 764-6 [10363888.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5694-9 [15531530.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1835-41 [15505628.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):77-85 [15652751.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):260-8 [15609347.001]
  • [Cites] Eur J Pediatr. 2004 Dec;163(12):701-3 [15365827.001]
  • [Cites] Eur J Endocrinol. 2005 Jan;152(1):87-94 [15762191.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1894-901 [15774781.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):161-72 [15788647.001]
  • [Cites] Hum Genet. 2003 Aug;113(3):228-37 [12811540.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1375-80 [12883710.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5615-21 [14500403.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4932-7 [14557476.001]
  • [Cites] J Pathol. 2003 Nov;201(3):480-6 [14595761.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):153-9 [14685938.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):362-7 [14715873.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):707-15 [14974911.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):728-33 [14974914.001]
  • [Cites] J Med Genet. 2004 Mar;41(3):e30 [14985401.001]
  • [Cites] Clin Genet. 2004 Jan;65(1):61-3 [15032977.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 15;150(2):128-35 [15066320.001]
  • [Cites] Oncogene. 2004 May 20;23(23):4076-83 [15064708.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):706-11 [15220362.001]
  • [Cites] J Med Genet. 2004 Jul;41(7):e99 [15235042.001]
  • [Cites] JAMA. 2004 Aug 25;292(8):943-51 [15328326.001]
  • [Cites] J Med Genet. 2004 Sep;41(9):703-9 [15342702.001]
  • [Cites] BMC Cancer. 2004 Aug 24;4:55 [15331017.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1409-10 [15371856.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Oct;61(4):510-4 [15473885.001]
  • [Cites] Eur J Endocrinol. 2004 Oct;151(4):433-8 [15476441.001]
  • [Cites] Clin Genet. 2004 Nov;66(5):461-6 [15479192.001]
  • [Cites] Cancer. 1974 Nov;34(5):1787-95 [4371947.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):2116-22 [7000334.001]
  • [Cites] J Natl Cancer Inst. 1982 Apr;68(4):573-8 [6951072.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2110-6 [15644401.001]
  • [Cites] Fam Cancer. 2005;4(1):49-54 [15883710.001]
  • [Cites] Diagn Mol Pathol. 2005 Jun;14(2):109-14 [15905695.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3773-9 [15741255.001]
  • [Cites] J Intern Med. 2005 Jul;258(1):55-66 [15953133.001]
  • [Cites] Hum Mol Genet. 2005 Aug 1;14(15):2231-9 [15987702.001]
  • [Cites] J Med Genet. 2005 Aug;42(8):e48 [16061554.001]
  • [Cites] J Med Genet. 2005 Aug;42(8):e52 [16061558.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2449-52 [16080474.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2809-14 [16080530.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):155-67 [16098468.001]
  • [Cites] Neurogenetics. 1999 Sep;2(3):167-70 [10541590.001]
  • [Cites] FEBS Lett. 2000 Jan 21;466(1):1-5 [10648801.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):651-9 [10666394.001]
  • [Cites] J Clin Invest. 2000 Feb;105(4):401-7 [10683367.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):353-9 [10934139.001]
  • [Cites] Nat Genet. 2000 Nov;26(3):268-70 [11062460.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:156-65 [17102082.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:166-76 [17102083.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:183-9 [17102085.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:190-7 [17102086.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):702-6; quiz following 706 [17143317.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):779-86 [17200167.001]
  • [Cites] Hong Kong Med J. 2007 Apr;13(2):151-4 [17406045.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Apr;92(4):1245-8 [17227803.001]
  • [Cites] Endocrine. 2006 Dec;30(3):307-12 [17526943.001]
  • [Cites] Eur J Clin Invest. 2007 Jul;37(7):544-51 [17576205.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jul;92(7):2784-92 [17426081.001]
  • [Cites] Horm Res. 2007;68(2):68-71 [17308434.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):453-62 [17639058.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):306-8 [17634472.001]
  • [Cites] J Med Genet. 2007 Sep;44(9):586-7 [17557926.001]
  • [Cites] N Engl J Med. 2007 Sep 6;357(10):1054-6 [17804857.001]
  • [Cites] Head Neck. 2007 Sep;29(9):864-73 [17563904.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10):1578-85 [17895761.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Oct;4(10):608-12 [17898811.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3822-8 [17652212.001]
  • (PMID = 19522823.001).
  • [ISSN] 1365-2796
  • [Journal-full-title] Journal of internal medicine
  • [ISO-abbreviation] J. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / Z01 HD000642; United States / Intramural NIH HHS / / ZIA HD000642-13; United States / NICHD NIH HHS / HD / Z01-HD-000642-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.3.99.1 / Succinate Dehydrogenase
  • [Number-of-references] 157
  • [Other-IDs] NLM/ NIHMS305487; NLM/ PMC3163304
  •  go-up   go-down


16. Leth-Larsen R, Lund RR, Ditzel HJ: Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics; 2010 Jul;9(7):1369-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Membrane / chemistry. Membrane Proteins / metabolism. Neoplasms / metabolism. Proteome / metabolism. Proteomics / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2005 May;23(5):617-21 [15834404.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4645-52 [15930282.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jun;4(6):477-88 [15931257.001]
  • [Cites] Expert Rev Proteomics. 2005 Jan;2(1):87-101 [15966855.001]
  • [Cites] Mol Cell Proteomics. 2005 Jul;4(7):873-86 [15858219.001]
  • [Cites] J Chromatogr A. 2005 Jun 3;1077(1):1-18 [15988981.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):526-42 [16069816.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3262-77 [16052621.001]
  • [Cites] Stem Cells. 2005 Oct;23(9):1367-77 [16210410.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1187-97 [16230073.001]
  • [Cites] Nat Clin Pract Oncol. 2004 Dec;1(2):104-11 [16264828.001]
  • [Cites] Mol Cell Proteomics. 2005 Nov;4(11):1741-53 [16091476.001]
  • [Cites] J Proteome Res. 2005 Nov-Dec;4(6):1952-60 [16335939.001]
  • [Cites] J Proteome Res. 2005 Nov-Dec;4(6):2148-53 [16335961.001]
  • [Cites] Mol Cell Proteomics. 2006 Jan;5(1):68-78 [16216825.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):2833-43 [16493040.001]
  • [Cites] BMC Cancer. 2006;6:68 [16542425.001]
  • [Cites] J Exp Bot. 2006;57(7):1501-8 [16574745.001]
  • [Cites] J Proteome Res. 2006 May;5(5):1051-9 [16674093.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jun;7(6):391-403 [16723975.001]
  • [Cites] Biotechniques. 2006 Jun;40(6):790-8 [16774123.001]
  • [Cites] Mol Cell Proteomics. 2008 Apr;7(4):661-71 [18039691.001]
  • [Cites] Mol Cell Proteomics. 2008 Apr;7(4):813-23 [18089551.001]
  • [Cites] Curr Protoc Protein Sci. 2001 May;Chapter 13:Unit13.1 [18429113.001]
  • [Cites] J Proteome Res. 2008 May;7(5):1809-18 [18327898.001]
  • [Cites] J Proteome Res. 2008 May;7(5):1904-15 [18410138.001]
  • [Cites] Analyst. 2008 Jun;133(6):731-8 [18493671.001]
  • [Cites] J Cell Mol Med. 2008 Jun;12(3):829-75 [18266954.001]
  • [Cites] Proteomics. 2008 May;8(10):1987-2005 [18491314.001]
  • [Cites] Methods Mol Biol. 2008;484:263-76 [18592185.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1166-75 [18487288.001]
  • [Cites] Anal Chem. 2008 Jul 15;80(14):5286-92 [18558770.001]
  • [Cites] Mol Cell Biol. 2008 Aug;28(15):4896-914 [18505826.001]
  • [Cites] J Proteome Res. 2008 Aug;7(8):3304-13 [18578522.001]
  • [Cites] Proteomics. 2008 Aug;8(16):3284-93 [18646009.001]
  • [Cites] Proteomics. 2008 Aug;8(16):3236-56 [18651673.001]
  • [Cites] Proteomics. 2008 Aug;8(16):3263-73 [18690645.001]
  • [Cites] Int J Clin Oncol. 2008 Aug;13(4):308-13 [18704630.001]
  • [Cites] Neoplasia. 2008 Sep;10(9):1014-20 [18714363.001]
  • [Cites] Cancer. 2008 Sep 15;113(6):1294-301 [18661530.001]
  • [Cites] J Biol Chem. 2008 Sep 26;283(39):26518-27 [18658134.001]
  • [Cites] Proteomics. 2008 Oct;8(19):4146-55 [18763708.001]
  • [Cites] Proteomics. 2008 Oct;8(19):4054-65 [18780347.001]
  • [Cites] J Proteome Res. 2008 Oct;7(10):4313-25 [18729497.001]
  • [Cites] Proteomics. 2010 Feb;10(4):611-27 [19834916.001]
  • [Cites] J Proteome Res. 2010 Mar 5;9(3):1610-8 [20088484.001]
  • [Cites] J Proteome Res. 2008 Nov;7(11):4670-7 [18839982.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2802-11 [17539671.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):509-17 [17559147.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4652-4 [17671159.001]
  • [Cites] Cell. 2007 Aug 10;130(3):395-8 [17693247.001]
  • [Cites] Lab Invest. 2007 Sep;87(9):851-7 [17632542.001]
  • [Cites] Proteomics. 2007 Aug;7(16):3010-29 [17654460.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):659-72 [17721431.001]
  • [Cites] J Proteome Res. 2007 Sep;6(9):3491-500 [17663576.001]
  • [Cites] Mol Cell Proteomics. 2007 Oct;6(10):1778-87 [17623646.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):388-94 [18199532.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):5-10 [18066649.001]
  • [Cites] Fundam Clin Pharmacol. 2008 Feb;22(1):1-18 [18251718.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1002-14 [18281532.001]
  • [Cites] Methods Mol Biol. 2008;428:43-53 [18287767.001]
  • [Cites] BJU Int. 2008 Mar;101(6):675-83 [17941930.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):571-9 [18385731.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1419-26 [18303830.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1403-11 [18311906.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):4-8 [10580125.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] J Mol Biol. 2001 Jan 19;305(3):567-80 [11152613.001]
  • [Cites] Physiol Genomics. 2001 Apr 2;5(3):129-36 [11285366.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3376-84 [11454885.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Nov;134(11):1229-35 [18438684.001]
  • [Cites] Mol Cell Proteomics. 2008 Oct;7(10):1983-97 [18490355.001]
  • [Cites] Proteomics. 2008 Nov;8(21):4370-82 [18814326.001]
  • [Cites] Virchows Arch. 2008 Dec;453(6):537-43 [18958494.001]
  • [Cites] Int J Cancer. 2008 Dec 15;123(12):2856-64 [18798264.001]
  • [Cites] Biochemistry (Mosc). 2008 Nov;73(11):1200-6 [19120023.001]
  • [Cites] Breast Cancer Res. 2008;10(5):R85 [18922159.001]
  • [Cites] Dis Markers. 2008;25(4-5):207-18 [19126965.001]
  • [Cites] J Proteome Res. 2009 Feb;8(2):583-94 [19086899.001]
  • [Cites] J Proteome Res. 2009 Feb;8(2):643-50 [19099503.001]
  • [Cites] J Hepatol. 2009 Mar;50(3):592-603 [19157620.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):803-14 [19060928.001]
  • [Cites] Glycoconj J. 2009 Feb;26(2):117-31 [18752066.001]
  • [Cites] J Proteomics. 2009 Feb 15;72(1):12-22 [18926938.001]
  • [Cites] Proteomics. 2009 Mar;9(6):1451-68 [19235172.001]
  • [Cites] J Lipid Res. 2009 Apr;50 Suppl:S323-8 [18955730.001]
  • [Cites] Mol Oncol. 2007 Sep;1(2):144-59 [18443658.001]
  • [Cites] Breast Cancer Res Treat. 2009 May;115(1):77-85 [18521745.001]
  • [Cites] Expert Rev Proteomics. 2009 Apr;6(2):115-8 [19385938.001]
  • [Cites] Proteomics. 2009 Apr;9(8):2118-30 [19337990.001]
  • [Cites] Brief Funct Genomic Proteomic. 2009 Mar;8(2):136-44 [19151093.001]
  • [Cites] Cancer Treat Rev. 2009 Jun;35(4):354-63 [19269105.001]
  • [Cites] FEBS Lett. 2009 Jun 5;583(11):1728-35 [19328791.001]
  • [Cites] Mol Cell Proteomics. 2009 Jun;8(6):1436-49 [19321434.001]
  • [Cites] Mol Cell Proteomics. 2009 Jun;8(6):1278-94 [19329653.001]
  • [Cites] J Proteome Res. 2009 Jun;8(6):3078-90 [19341246.001]
  • [Cites] J Proteome Res. 2009 Jun;8(6):2656-66 [19441788.001]
  • [Cites] J Proteome Res. 2009 Mar;8(3):1358-67 [19178301.001]
  • [Cites] Clin Transl Oncol. 2009 Jun;11(6):356-62 [19531450.001]
  • [Cites] Glycobiology. 2009 Aug;19(8):899-909 [19433864.001]
  • [Cites] Mol Cell Proteomics. 2009 Jul;8(7):1453-74 [19297561.001]
  • [Cites] J Proteome Res. 2009 Aug;8(8):4151-60 [19522481.001]
  • [Cites] J Proteome Res. 2009 Aug;8(8):3808-15 [19537829.001]
  • [Cites] Mol Cell Proteomics. 2009 Aug;8(8):1959-71 [19457934.001]
  • [Cites] Mol Cell Proteomics. 2009 Aug;8(8):1988-98 [19467989.001]
  • [Cites] Hum Pathol. 2009 Oct;40(10):1418-26 [19428047.001]
  • [Cites] J Proteome Res. 2009 Nov;8(11):5048-59 [19764822.001]
  • [Cites] Am J Clin Pathol. 2009 Dec;132(6):899-905 [19926582.001]
  • [Cites] Mol Cell Proteomics. 2009 Nov;8(11):2595-612 [19674965.001]
  • [Cites] Anal Bioanal Chem. 2009 Dec;395(8):2443-56 [19876624.001]
  • [Cites] J Proteomics. 2010 Jan 3;73(3):579-92 [19666151.001]
  • [Cites] Anal Chem. 2001 Jul 1;73(13):2836-42 [11467524.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):355-64 [11547903.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1255-60 [11710941.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:526-32 [12454649.001]
  • [Cites] Electrophoresis. 2002 Dec;23(24):4142-56 [12481271.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] J Proteome Res. 2002 Jul-Aug;1(4):351-60 [12645891.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6940-5 [12771378.001]
  • [Cites] J Pathol. 2003 Aug;200(5):620-6 [12898598.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):203-9 [14499014.001]
  • [Cites] Am Fam Physician. 2003 Sep 15;68(6):1075-82 [14524394.001]
  • [Cites] Mol Cell Proteomics. 2003 Nov;2(11):1198-204 [14506205.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] Clin Chem Lab Med. 2003 Dec;41(12):1562-70 [14708880.001]
  • [Cites] Breast Cancer Res Treat. 2004 Feb;83(3):249-89 [14758095.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):831-40 [14982837.001]
  • [Cites] Anal Chem. 2004 Apr 1;76(7):1817-23 [15053638.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):361-70 [15122207.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):556-66 [15253437.001]
  • [Cites] Ann Surg Oncol. 2004 Oct;11(10):907-14 [15383419.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:839-66 [15473862.001]
  • [Cites] Mol Cell Proteomics. 2004 Oct;3(10):1023-38 [15284337.001]
  • [Cites] Annu Rev Biochem. 1972;41:731-52 [4263713.001]
  • [Cites] Nature. 1975 Nov 6;258(5530):43-9 [1102991.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 1993;22:145-71 [8347987.001]
  • [Cites] J Chromatogr A. 1996 Jan 12;720(1-2):119-26 [8601188.001]
  • [Cites] Glycoconj J. 1997 Aug;14(5):569-76 [9298689.001]
  • [Cites] Protein Sci. 1998 Apr;7(4):1029-38 [9568909.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1451-67 [9605801.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:212-27 [10415733.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):779-84 [15642945.001]
  • [Cites] Anal Chem. 2005 Feb 1;77(3):886-94 [15679358.001]
  • [Cites] Electrophoresis. 2005 Jan;26(2):297-319 [15657944.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):402-8 [15684408.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):492-522 [15695426.001]
  • [Cites] J Chromatogr A. 2005 Apr 8;1070(1-2):57-64 [15861788.001]
  • [Cites] Cell Mol Life Sci. 2006 Jun;63(12):1331-54 [16596337.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4377s-4383s [16857814.001]
  • [Cites] Clin Chem. 2006 Sep;52(9):1651-9 [16809399.001]
  • [Cites] Int J Biol Markers. 2006 Jul-Sep;21(3):131-40 [17013794.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14889-94 [17001009.001]
  • [Cites] J Proteome Res. 2006 Oct;5(10):2632-41 [17022634.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1957-67 [16760258.001]
  • [Cites] J Proteome Res. 2006 Nov;5(11):2996-3007 [17081051.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2337-45 [17048231.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Dec;7(12):952-8 [17139335.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1766(2):230-41 [16889898.001]
  • [Cites] Mol Cell Proteomics. 2006 Dec;5(12):2319-25 [16943187.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):65-76 [16799640.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):43-55 [16847285.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e107 [17238276.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):79-94 [17251915.001]
  • [Cites] J Pharm Biomed Anal. 2007 Feb 19;43(3):1086-93 [17085005.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):835-44 [17321128.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):828-34 [17329097.001]
  • [Cites] Genome Biol. 2006;7(8):R73 [16901351.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):1979-86 [17404077.001]
  • [Cites] Nat Protoc. 2006;1(2):1029-43 [17406340.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5860-5 [17389395.001]
  • (PMID = 20382631.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Proteome
  • [Other-IDs] NLM/ PMC2938092
  •  go-up   go-down


17. Thomas JL, Mack VL, Sun J, Terrell JR, Bucholtz KM: The functions of key residues in the inhibitor, substrate and cofactor sites of human 3beta-hydroxysteroid dehydrogenase type 1 are validated by mutagenesis. J Steroid Biochem Mol Biol; 2010 Jun;120(4-5):192-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In postmenopausal women, human 3beta-hydroxysteroid dehydrogenase type 1 (3beta-HSD1) is a critical enzyme in the conversion of DHEA to estradiol in breast tumors, while 3beta-HSD2 participates in the production of cortisol and aldosterone in the human adrenal gland.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16778-85 [14966133.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35483-90 [12832414.001]
  • [Cites] J Mol Endocrinol. 2004 Aug;33(1):253-61 [15291757.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Steroid Biochem. 1988 Nov;31(5):785-93 [3199818.001]
  • [Cites] J Steroid Biochem. 1989 Aug;33(2):209-17 [2770297.001]
  • [Cites] Mol Endocrinol. 1991 Aug;5(8):1147-57 [1944309.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] Biochemistry. 1995 May 9;34(18):6003-13 [7742302.001]
  • [Cites] Biochemistry. 1996 Feb 27;35(8):2557-66 [8611559.001]
  • [Cites] J Endocrinol. 1996 Sep;150 Suppl:S189-207 [8943802.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):267-71 [9365200.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):735-9 [9398055.001]
  • [Cites] J Steroid Biochem Mol Biol. 1998 Sep;66(5-6):327-34 [9749838.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):66-81 [9892013.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Sep;101(1):50-60 [16889958.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Oct;107(1-2):80-7 [17624763.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Jul;111(1-2):66-73 [18524572.001]
  • [Cites] Chem Biol Interact. 2009 Mar 16;178(1-3):94-8 [19027726.001]
  • [Cites] Mol Cell Endocrinol. 2009 Mar 25;301(1-2):174-82 [18955108.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25677-84 [11976334.001]
  • [Cites] Trends Endocrinol Metab. 2002 Aug;13(6):234-9 [12128283.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):42795-801 [12205101.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 7;1654(2):123-43 [15172700.001]
  • (PMID = 20420909.001).
  • [ISSN] 1879-1220
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA114717-21; United States / NCI NIH HHS / CA / R01 CA114717; United States / NCI NIH HHS / CA / CA114717; United States / NCI NIH HHS / CA / R01 CA114717-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acids; 08J2K08A3Y / Dihydrotestosterone; 459AG36T1B / Dehydroepiandrosterone; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases; L0FPV48Q5R / trilostane
  • [Other-IDs] NLM/ NIHMS200209; NLM/ PMC2891085
  •  go-up   go-down


18. Zhao J, Patwa TH, Lubman DM, Simeone DM: Protein biomarkers in cancer: natural glycoprotein microarray approaches. Curr Opin Mol Ther; 2008 Dec;10(6):602-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Protein glycosylation is the most versatile and common protein modification and plays important roles in various biological processes and disease progression.
  • These techniques show great promise for detecting interactions that involve carbohydrates and as a screening tool to detect glycan patterns important for the early diagnosis of disease.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2000 Jun;46(6 Pt 1):795-805 [10839767.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1693-703 [18311904.001]
  • [Cites] Science. 2001 Mar 23;291(5512):2370-6 [11269318.001]
  • [Cites] Glycoconj J. 2000 Jul-Sep;17(7-9):553-65 [11421348.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):355-64 [11547903.001]
  • [Cites] Nat Biotechnol. 2002 Mar;20(3):275-81 [11875429.001]
  • [Cites] FEBS Lett. 2002 Apr 10;516(1-3):217-24 [11959136.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26103-12 [12000758.001]
  • [Cites] Glycobiology. 2003 Apr;13(4):227-44 [12626415.001]
  • [Cites] Glycobiology. 2003 Jun;13(6):457-70 [12626390.001]
  • [Cites] Glycoconj J. 2001 Nov-Dec;18(11-12):841-50 [12820717.001]
  • [Cites] Proteomics. 2003 Jul;3(7):1228-35 [12872223.001]
  • [Cites] Curr Opin Struct Biol. 2003 Oct;13(5):637-45 [14568620.001]
  • [Cites] Glycobiology. 2004 Feb;14(2):197-203 [14638630.001]
  • [Cites] Angew Chem Int Ed Engl. 2004 Mar 12;43(12):1591-4 [15022242.001]
  • [Cites] Chem Biol. 2004 Jun;11(6):875-81 [15217620.001]
  • [Cites] Physiol Genomics. 2004 Jul 8;18(2):245-8 [15161967.001]
  • [Cites] Br J Cancer. 1987 Mar;55(3):249-54 [2436644.001]
  • [Cites] Annu Rev Biochem. 1987;56:21-42 [3304133.001]
  • [Cites] Cancer Res. 1989 Oct 1;49(19):5317-22 [2766300.001]
  • [Cites] Gut. 1991 Mar;32(3):287-93 [1826491.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3138-44 [1350509.001]
  • [Cites] J Cell Biol. 1995 Jul;130(2):383-92 [7615638.001]
  • [Cites] Ann Clin Biochem. 1998 May;35 ( Pt 3):364-70 [9635101.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):362-71 [10197444.001]
  • [Cites] Mol Cell Proteomics. 2004 Nov;3(11):1102-18 [15358805.001]
  • [Cites] Glycobiology. 2005 Jan;15(1):87-100 [15317738.001]
  • [Cites] Glycobiology. 2005 Jan;15(1):31-41 [15342550.001]
  • [Cites] Chembiochem. 2005 May;6(5):782-99 [15791688.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jun;4(6):477-88 [15931257.001]
  • [Cites] Chembiochem. 2005 Jun;6(6):985-9 [15798991.001]
  • [Cites] Anal Chem. 2005 Jul 1;77(13):4081-90 [15987113.001]
  • [Cites] Immunol Cell Biol. 2005 Aug;83(4):429-39 [16033539.001]
  • [Cites] Nat Methods. 2005 Nov;2(11):851-6 [16278656.001]
  • [Cites] Anal Chem. 2005 Nov 15;77(22):7225-31 [16285669.001]
  • [Cites] Chembiochem. 2005 Dec;6(12):2229-41 [16252298.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):15-20 [16373501.001]
  • [Cites] J Am Chem Soc. 2006 Mar 8;128(9):2766-7 [16506732.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1626-35 [16823970.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1792-802 [16823988.001]
  • [Cites] Anal Chem. 2006 Sep 15;78(18):6411-21 [16970316.001]
  • [Cites] Clin Chem. 2006 Oct;52(10):1897-905 [16916992.001]
  • [Cites] J Proteome Res. 2006 Oct;5(10):2691-700 [17022640.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1957-67 [16760258.001]
  • [Cites] Nat Rev Microbiol. 2006 Nov;4(11):857-64 [17013397.001]
  • [Cites] Methods Enzymol. 2006;415:341-51 [17116484.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):56-62 [17218853.001]
  • [Cites] J Proteome Res. 2007 Mar;6(3):1126-38 [17249709.001]
  • [Cites] J Biochem Biophys Methods. 2007 Apr 10;70(3):415-26 [17112594.001]
  • [Cites] Nat Protoc. 2006;1(2):543-9 [17406280.001]
  • [Cites] Nat Methods. 2007 May;4(5):437-44 [17417647.001]
  • [Cites] J Proteome Res. 2007 May;6(5):1864-74 [17428079.001]
  • [Cites] Science. 2001 Mar 23;291(5512):2357-64 [11269316.001]
  • (PMID = 19051138.001).
  • [ISSN] 1464-8431
  • [Journal-full-title] Current opinion in molecular therapeutics
  • [ISO-abbreviation] Curr. Opin. Mol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106402; United States / NCI NIH HHS / CA / R01CA106402; United States / NIGMS NIH HHS / GM / R01 GM049500-12; United States / NCI NIH HHS / CA / R21 CA124441; United States / NIGMS NIH HHS / GM / R01GM49500; United States / NIGMS NIH HHS / GM / GM049500-12; United States / NIGMS NIH HHS / GM / R01 GM049500; United States / NCI NIH HHS / CA / R01 CA106402-05; United States / NCI NIH HHS / CA / R21 CA124441-02; United States / NCI NIH HHS / CA / R21CA124441
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Lectins
  • [Number-of-references] 54
  • [Other-IDs] NLM/ NIHMS225469; NLM/ PMC2920894
  •  go-up   go-down


19. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP: Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics; 2009 Apr;8(4):661-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Ascites / metabolism. Biomarkers, Tumor / analysis. Ovarian Neoplasms / metabolism. Proteome / analysis
  • [MeSH-minor] Chemical Fractionation. Chromatography, Gel. Chromatography, Liquid. Female. Humans. Kallikreins / analysis. Mass Spectrometry. Neoplasm Proteins / analysis. Neoplasm Proteins / chemistry. Protein Transport. Subcellular Fractions / metabolism. Ultrafiltration

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2008 Jan;7(1):339-51 [18076136.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Cell Biochem Biophys. 2007;49(3):182-95 [17952643.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):569-72 [10769727.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:45-50 [10804091.001]
  • [Cites] Clin Biochem. 2000 Jul;33(5):369-75 [11018688.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3903-6 [11268474.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7293-300 [11704858.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1353-7 [11762804.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1917-24 [12414537.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):807-11 [12591730.001]
  • [Cites] Tumour Biol. 2002 Sep-Oct;23(5):303-14 [12595747.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1035-43 [12637468.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):433-40 [12882527.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Clin Chem. 2004 Apr;50(4):709-16 [14764643.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):999-1011 [15194082.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Jul;31(7):1003-7 [15272576.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1981-5 [15274388.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Neoplasma. 1979;26(6):737-43 [44348.001]
  • [Cites] Tokai J Exp Clin Med. 1982 May;7(3):325-9 [6896935.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1985 Jun;19(6):354-6 [4018373.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] PLoS One. 2008;3(6):e2425 [18560578.001]
  • [Cites] J Transl Med. 2008;6:41 [18652693.001]
  • [Cites] Cancer Treat Rev. 1995 May;21(3):215-45 [7656266.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2799-804 [8669868.001]
  • [Cites] Biochem Pharmacol. 1997 Sep 1;54(5):541-4 [9337069.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1843-9 [9581823.001]
  • [Cites] J Biomol Tech. 2004 Dec;15(4):238-48 [15585820.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):837-45 [15952730.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2885-9 [16080542.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3292-303 [16052620.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3304-13 [16052628.001]
  • [Cites] Proteomics. 2005 Oct;5(15):4034-45 [16152657.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):267-77 [16061277.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):316-9 [16240401.001]
  • [Cites] BMC Cancer. 2005;5:133 [16225703.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4625-36 [16220531.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4589-96 [16237736.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):656-63 [16112717.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1399-410 [16738170.001]
  • [Cites] Genome Biol. 2006;7(5):R40 [16709260.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66 [17255266.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):435-42 [17023034.001]
  • [Cites] Genome Biol. 2006;7(8):R72 [16901338.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2426-34 [17294443.001]
  • [Cites] J Proteome Res. 2007 May;6(5):1728-34 [17397210.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2859-65 [17567164.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4422-8 [17671125.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4C):2753-8 [17695443.001]
  • [Cites] Mol Cell Proteomics. 2007 Aug;6(8):1406-15 [17495049.001]
  • [Cites] J Cell Biochem. 1990 May;43(1):43-57 [2189881.001]
  • [Cites] J Clin Invest. 1993 Nov;92(5):2160-7 [8227331.001]
  • [Cites] Tumour Biol. 1993;14(6):360-8 [8265982.001]
  • [Cites] Mol Cell Proteomics. 2007 Nov;6(11):1997-2011 [17656355.001]
  • [Cites] J Proteome Res. 2007 Dec;6(12):4549-55 [17970587.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7370-9 [18094419.001]
  • (PMID = 19047685.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Proteome; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  • [Other-IDs] NLM/ PMC2667349
  •  go-up   go-down


20. Chetty R, Serra S, Hsieh E: Basaloid squamous carcinoma of the anal canal with an adenoid cystic pattern: histologic and immunohistochemical reappraisal of an unusual variant. Am J Surg Pathol; 2005 Dec;29(12):1668-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous carcinoma of the anal canal with an adenoid cystic pattern: histologic and immunohistochemical reappraisal of an unusual variant.
  • Two cases of a distinctive variety of basaloid squamous carcinoma (BSC) of the anal canal are described.
  • However, the microscopic pattern was dominated by the presence of eosinophilic, hyaline, paucicellular basement membrane-like material around and within tumor nests.
  • The tumor cells exhibited diffuse nuclear positivity with p63.
  • BSC of the anal canal with an adenoid cystic pattern is an infrequently encountered and reported variant, although it is seen more often in the aerodigestive tract.
  • The histologic differential diagnosis is true salivary gland-type adenoid cystic carcinoma and basal cell adenocarcinoma.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Basosquamous / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Antigens, CD20 / metabolism. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cisplatin / therapeutic use. DNA-Binding Proteins. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Middle Aged. Mitomycin / therapeutic use. Phosphoproteins / metabolism. Radiotherapy. Time Factors. Trans-Activators / metabolism. Transcription Factors. Treatment Outcome. Tumor Burden. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327441.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD20; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 50SG953SK6 / Mitomycin; 68238-35-7 / Keratins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Wakatsuki K, Oeda Y, Isono T, Yoshioka S, Nukui Y, Yamazaki K, Nabeshima S, Miyazaki M: Adenocarcinoma of the rectosigmoid colon seeding into pre-existing anal fistula. Hepatogastroenterology; 2008 May-Jun;55(84):952-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the rectosigmoid colon seeding into pre-existing anal fistula.
  • This paper reports a rare case of rectosigmoid colon carcinoma metastasizing to anal fistula.
  • Two years and 3 months later, a subcutaneous tumor was found at the external opening of fistula.
  • Trans perineal tumor excision plus fistulectomy was performed.
  • Pathology revealed that the colon cancer and the perianal tumor were both moderately differentiated adenocarcinoma.
  • Many reports support the concept of tumor cell implantation in mucosa that have been altered or denuded by various factors.
  • Sixteen reports could be found of implantation metastasis of colorectal cancer into anal fistula.
  • In diagnosis, it is important to differentiate implantation of colorectal cancer in anal fistula from primary anal fistular adenocarcinoma.
  • The histology of the perianal tumor in this patient closely resembles the tumor of the colon.
  • Furthermore, immunohistochemistry for cytokeratins 7 and 20 was performed on tissues to distinguish colorectal adenocarcinoma from anal gland carcinoma.
  • Both colorectal cancer and perianal tumor showed CK7-/CK20+.
  • [MeSH-major] Adenocarcinoma / secondary. Anus Neoplasms / secondary. Neoplasm Seeding. Rectal Fistula / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Colon, Sigmoid / pathology. Colon, Sigmoid / surgery. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Reoperation

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705305.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


22. Sameni M, Cavallo-Medved D, Dosescu J, Jedeszko C, Moin K, Mullins SR, Olive MB, Rudy D, Sloane BF: Imaging and quantifying the dynamics of tumor-associated proteolysis. Clin Exp Metastasis; 2009;26(4):299-309
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging and quantifying the dynamics of tumor-associated proteolysis.
  • Proteases from tumor-associated cells (e.g., fibroblasts, inflammatory cells, endothelial cells) as well as from tumor cells make important contributions to 'tumor proteolysis'.
  • Here we describe live cell assays for imaging proteolysis, protocols for quantifying proteolysis and the use of such assays to follow the dynamics of proteolysis by tumor cells alone and tumor cells interacting with other cells found in the tumor microenvironment.
  • In addition, we describe an in vitro model that recapitulates the architecture of the mammary gland, a model designed to determine the effects of dynamic interactions with the surrounding microenvironment on 'tumor proteolysis' and the respective contributions of various cell types to 'tumor proteolysis'.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2003;5(3):130-5 [12793893.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:301-15 [16402907.001]
  • [Cites] Nat Chem Biol. 2005 Sep;1(4):203-9 [16408036.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):608-22 [16442099.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):716-28 [16469948.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5242-50 [16707449.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11238-46 [17114237.001]
  • [Cites] Curr Opin Chem Biol. 2007 Feb;11(1):36-45 [17194619.001]
  • [Cites] Curr Pharm Des. 2007;13(3):253-61 [17313359.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2086-95 [17290405.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2007 Mar;12(1):83-97 [17286208.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2850-8 [17547438.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):893-904 [17618273.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):800-8 [17851543.001]
  • [Cites] Nat Methods. 2007 Oct;4(10):822-7 [17901872.001]
  • [Cites] Rev Endocr Metab Disord. 2007 Sep;8(3):279-87 [17447144.001]
  • [Cites] Birth Defects Res C Embryo Today. 2007 Dec;81(4):270-85 [18228260.001]
  • [Cites] Neoplasia. 2008 Apr;10(4):314-29 [18392133.001]
  • [Cites] J Clin Neurosci. 2008 Jul;15(7):725-37 [18468901.001]
  • [Cites] Biol Chem. 2008 Aug;389(8):1117-21 [18710343.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1185-6 [10904098.001]
  • [Cites] Exp Cell Res. 2000 Nov 1;260(2):292-303 [11035924.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):496-504 [11228542.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):169-84 [11237532.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6642-50 [11426650.001]
  • [Cites] Biol Chem. 2001 May;382(5):785-8 [11517931.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Science. 2002 May 10;296(5570):1046-9 [12004111.001]
  • [Cites] Breast Cancer Res. 2003;5(3):140-6 [12793895.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Hum Cell. 2003 Mar;16(1):1-14 [12971620.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S127-33 [14508090.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Anal Bioanal Chem. 2003 Nov;377(6):956-63 [12955390.001]
  • [Cites] Mol Imaging. 2003 Jul;2(3):159-75 [14649059.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91 [14973383.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 4;1654(1):13-22 [14984764.001]
  • [Cites] Histochem Cell Biol. 2004 Apr;121(4):299-310 [15042374.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Front Biol. 1975;43(4):193-249 [780142.001]
  • [Cites] Lab Invest. 1978 Dec;39(6):531-40 [216851.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Mol Carcinog. 1991;4(1):25-35 [2009132.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] Breast Cancer Res. 2004;6(2):93-101 [14979914.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1163-76 [15841211.001]
  • [Cites] J Cell Biol. 2005 Jun 20;169(6):977-85 [15967816.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Jun;5(4):285-98 [15975049.001]
  • [Cites] Semin Cancer Biol. 2005 Oct;15(5):342-52 [15963732.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):675-88 [16148884.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6870-6 [16007139.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1093-107 [16306453.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):97-104 [12027581.001]
  • [Cites] Cell. 2002 Oct 4;111(1):29-40 [12372298.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Expert Opin Ther Targets. 2003 Feb;7(1):71-88 [12556204.001]
  • [Cites] Breast Cancer Res. 2003;5(1):31-6 [12559043.001]
  • [Cites] Breast Cancer Res. 2003;5(2):101-6 [12631389.001]
  • [Cites] J Histochem Cytochem. 2003 Jun;51(6):821-9 [12754293.001]
  • [Cites] Cancer Cell. 2003 May;3(5):445-8 [12781362.001]
  • (PMID = 19082919.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA056586-17; United States / NCI NIH HHS / CA / R01 CA131990; United States / NCI NIH HHS / CA / R01 CA056586; United States / NCI NIH HHS / CA / CA 56586; United States / NIEHS NIH HHS / ES / P30 ES006639; United States / NCI NIH HHS / CA / P30 CA022453; United States / NCI NIH HHS / CA / P30 CA 22453; United States / NCRR NIH HHS / RR / U54 RR 020843; United States / NIEHS NIH HHS / ES / P30 ES 06639; United States / NCI NIH HHS / CA / CA056586-17; United States / NCRR NIH HHS / RR / U54 RR020843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.- / Peptide Hydrolases
  • [Number-of-references] 70
  • [Other-IDs] NLM/ NIHMS223032; NLM/ PMC2991638
  •  go-up   go-down


23. de Noo ME, Tollenaar RA, Deelder AM, Bouwman LH: Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World J Gastroenterol; 2006 Nov 7;12(41):6594-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given the natural history of CRC, early diagnosis appears to be the most appropriate tool to reduce disease-related mortality.
  • (1) proteins being abnormally produced or shed and added to the serum proteome, (2) proteins clipped or modified as a consequence of the disease process, or (3) proteins subtracted from the proteome owing to disease-related proteolytic degradation pathways.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Proteomics / methods
  • [MeSH-minor] Biomarkers, Tumor / blood. Data Interpretation, Statistical. Humans. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2002 Dec;126(12):1518-26 [12456215.001]
  • [Cites] Proteomics. 2003 Jan;3(1):56-63 [12548634.001]
  • [Cites] Clin Chem. 2006 Jun;52(6):1045-53 [16574760.001]
  • [Cites] Semin Oncol. 2005 Feb;32(1):24-34 [15726503.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):233-7 [12634797.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):489-90; author reply 490-1 [12644546.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):243-52 [12671663.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):267-75 [12671665.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):433-40 [12882527.001]
  • [Cites] Bioinformatics. 2003 Aug 12;19(12):1484-91 [12912828.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2904-11 [12912935.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Trends Biotechnol. 2002 Dec;20(12 Suppl):S30-4 [12570157.001]
  • [Cites] Technol Cancer Res Treat. 2002 Aug;1(4):297-304 [12625789.001]
  • [Cites] Anal Chem. 2005 Nov 15;77(22):7232-41 [16285670.001]
  • [Cites] Clin Chem. 2005 Dec;51(12):2229-35 [16223889.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):26-30 [16395400.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):271-84 [16395409.001]
  • [Cites] J Pathol. 2006 Apr;208(5):595-606 [16518808.001]
  • [Cites] Proteomics. 2006 Apr;6(7):2095-100 [16502467.001]
  • [Cites] World J Gastroenterol. 2006 Mar 14;12(10):1536-44 [16570345.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1068-76 [16603345.001]
  • [Cites] Biostatistics. 2003 Jul;4(3):449-63 [12925511.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] J Proteome Res. 2003 Jul-Aug;2(4):361-72 [12938926.001]
  • [Cites] Proteomics. 2003 Sep;3(9):1667-72 [12973722.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6105-9 [14559785.001]
  • [Cites] BMC Bioinformatics. 2003 Jun 9;4:24 [12795817.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]
  • [Cites] Anal Chem. 2004 Mar 15;76(6):1560-70 [15018552.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):309-14 [15057290.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1448-53 [15131804.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2375-82 [15175439.001]
  • [Cites] World J Gastroenterol. 2004 Nov 1;10(21):3127-31 [15457557.001]
  • [Cites] Ann Intern Med. 1997 May 15;126(10):811-22 [9148658.001]
  • [Cites] Eur J Cancer. 2004 Nov;40(17):2613-22 [15541962.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):16-22 [15598930.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):378-91 [15637400.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):963-5 [15709159.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):291-2 [15765078.001]
  • [Cites] BMC Bioinformatics. 2005;6:68 [15788095.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 Feb;3(4):322-31 [15814023.001]
  • [Cites] Clin Sci (Lond). 2005 May;108(5):369-83 [15831087.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1685-95 [15887159.001]
  • [Cites] Clin Chem. 2005 Jun;51(6):973-80 [15845803.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1393-403 [15929776.001]
  • [Cites] Rapid Commun Mass Spectrom. 2005;19(12):1624-36 [15915451.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):972-81 [15952745.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5114-23 [16097747.001]
  • [Cites] Dig Surg. 2005;22(4):276-81 [16174984.001]
  • [Cites] Adv Exp Med Biol. 2000;477:349-78 [10849763.001]
  • [Cites] J Pathol. 2000 Nov;192(3):280-8 [11054709.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Jan;12(1):53-63 [11916161.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):132-41 [12118972.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):170; author reply 170-1 [12126845.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • (PMID = 17075970.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 69
  • [Other-IDs] NLM/ PMC4125662
  •  go-up   go-down


24. Visigalli D, Palmieri D, Strangio A, Astigiano S, Barbieri O, Casartelli G, Zicca A, Manduca P: The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts. BMC Cancer; 2009;9:59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We used a model of xenografts in BalbC/nude mice obtaining tumors by implanting in contro-lateral subcutaneous positions MDA MB231 cells added or not with purified PICP and studied the earlier phases of tumor development, up to 48 days from implant, by histology, immunostain and in situ hybridization.
  • RESULTS: Addition of PICP promotes rapid vascularization of the tumors while does not affect mitotic and apoptotic indexes and overall tumor growth.
  • PICP-treated, relative to control tumors, show up-modulation of Vascular endothelial factor, Metalloproteinase-9 and CXCR4, all tumor prognostic genes; they also show down-modulation of the endogenous Metalloproteinase inhibitor, reversion-inducing-cysteine-rich protein with kazal motifs, and a different pattern of modulation of Tissue Inhibitor of Metalloproteinase-2.
  • PICP may be play a relevant role in the productive interactions between stroma and tumor cells by predisposing the tumor cells to respond to the proliferation stimuli ensuing the activation of signaling by engagement of CXCR4 by cytokines and by fostering their extravasion, due to the induction of increased vascular development.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / pathology. Peptide Fragments / pharmacology. Procollagen / pharmacology
  • [MeSH-minor] Animals. Chemokine CXCL12 / biosynthesis. Chemokine CXCL12 / genetics. Female. Gene Expression / drug effects. Humans. In Situ Hybridization. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 9 / biosynthesis. Matrix Metalloproteinase 9 / genetics. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Metastasis. Neovascularization, Pathologic / enzymology. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, CXCR4 / biosynthesis. Receptors, CXCR4 / genetics. Transplantation, Heterologous. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Diagn. 1999 Sep;4(3):169-83 [10553018.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32658-63 [10924500.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] Cell. 2001 Dec 14;107(6):789-800 [11747814.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Breast Cancer Res Treat. 2002 Mar;72(1):69-77 [12000221.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3639-47 [12441353.001]
  • [Cites] Cell. 2003 Jul 25;114(2):171-80 [12887919.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5230-3 [14500350.001]
  • [Cites] Eur J Cell Biol. 2003 Nov;82(11):539-48 [14703010.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Anal Biochem. 1993 Nov 15;215(1):86-9 [7507651.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5517-20 [9407961.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13221-6 [9789069.001]
  • [Cites] J Pathol. 1998 Nov;186(3):262-8 [10211114.001]
  • [Cites] J Cell Sci. 2008 Oct 15;121(Pt 20):3487-95 [18843117.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1237-41 [10225966.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42 [15838603.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Oncogene. 2005 Sep 1;24(38):5850-7 [16007210.001]
  • [Cites] Breast. 2005 Oct;14(5):360-7 [16216737.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):35-43 [16680570.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):30-41 [16046252.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):283-90 [16924371.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2026-9 [16671092.001]
  • [Cites] Cancer Lett. 2007 Aug 8;253(1):34-42 [17306924.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(11):1987-94 [17719831.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1659-65 [17725805.001]
  • [Cites] Rev Endocr Metab Disord. 2007 Sep;8(3):279-87 [17447144.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):57-66 [18058195.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2050-6 [18172859.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):241-2 [18371356.001]
  • [Cites] Hum Pathol. 2008 May;39(5):731-9 [18329693.001]
  • [Cites] Exp Cell Res. 2008 Jul 1;314(11-12):2289-98 [18570923.001]
  • (PMID = 19226458.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Peptide Fragments; 0 / Procollagen; 0 / RNA, Messenger; 0 / Receptors, CXCR4; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / procollagen type I carboxy terminal peptide; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2652491
  •  go-up   go-down


25. Daniel AR, Lange CA: Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. Proc Natl Acad Sci U S A; 2009 Aug 25;106(34):14287-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells.
  • In advanced breast tumors, protein kinases are upregulated and steroid hormone receptors often function independently of ligand.
  • Herein, we explored mechanisms of ligand-independent progesterone receptor (PR) activity.
  • We showed previously that growth factor-induced phosphorylation of PR Ser-294 blocks PR Lys-388 sumoylation.
  • SUMO-deficient mutant PR-B (K388R) thus provides a model receptor for the study of PR function in the context of high kinase activities.
  • T47D cells stably expressing K388R PR-B exhibited increased ligand-independent proliferation and growth in soft agar relative to cells expressing wt PR-B or phospho-mutant (sumoylated) S294A PR-B.
  • Expression of selected PR target genes (HB-EGF, IRS-1, and STC1) was significantly elevated in cells containing desumoylated (K388R) PR-B.
  • Basal PR transcriptional activity occurred independently of progestins, was increased by activated CDK2, and attenuated by RU486.
  • Notably, ChIP assays demonstrated that K388R PR-B and SRC1 were constitutively recruited to the STC1 promoter in the absence of progestin; PR Lys-388 sumoylation was required for HDAC3 recruitment.
  • Knock-down of STC1 inhibited proliferation of cells expressing K388R PR-B.
  • These data suggest a mechanism whereby phosphorylated, and thus desumoylated, PRs mediate increased expression of growth promoting genes.
  • Our data explain why breast cancer models often remain insensitive to progestins, but are growth-inhibited by antiprogestins, and underscore the need to target PR-B and associated kinase activities as part of breast cancer therapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2001 Sep;21(18):6122-31 [11509655.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):627-35 [12566306.001]
  • [Cites] Mol Endocrinol. 2002 Mar;16(3):469-86 [11875105.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1289-95 [11888893.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33950-6 [12114521.001]
  • [Cites] Breast Cancer Res Treat. 2002 Mar;72(2):163-72 [12038707.001]
  • [Cites] Mol Endocrinol. 2003 Apr;17(4):628-42 [12554776.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):147-57 [12943699.001]
  • [Cites] Endocr Relat Cancer. 2003 Sep;10(3):359-73 [14503913.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):205-14 [14635795.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15758-63 [14663148.001]
  • [Cites] Mol Cell. 2004 Feb 27;13(4):611-7 [14992729.001]
  • [Cites] EMBO J. 1991 Nov;10(11):3331-41 [1655418.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3868-77 [8033109.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):5063-8 [7585552.001]
  • [Cites] Mol Endocrinol. 1997 Oct;11(11):1593-607 [9328342.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5076-81 [9560231.001]
  • [Cites] J Biol Chem. 1998 Nov 20;273(47):31308-16 [9813039.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10542-57 [15572662.001]
  • [Cites] Mol Endocrinol. 2005 Mar;19(3):574-87 [15563544.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61 [16145046.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Apr;28(2):111-4 [16637514.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1220-8 [17043687.001]
  • [Cites] Nucleic Acids Res. 2006;34(19):5552-66 [17020914.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(2):466-80 [17074804.001]
  • [Cites] Steroids. 2007 Feb;72(2):188-201 [17173941.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4199-209 [17483331.001]
  • [Cites] J Clin Invest. 2007 Aug;117(8):2205-15 [17627304.001]
  • [Cites] Mol Endocrinol. 2007 Dec;21(12):2890-906 [17717077.001]
  • [Cites] Mol Endocrinol. 2008 Apr;22(4):823-37 [18202149.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5745-9 [18408151.001]
  • [Cites] J Biol Chem. 2008 May 30;283(22):15224-31 [18403372.001]
  • [Cites] Adv Exp Med Biol. 2008;630:94-111 [18637487.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1032-7 [10655479.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5977-83 [11085516.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5209-18 [11717311.001]
  • (PMID = 19706513.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA123763; United States / NIDDK NIH HHS / DK / R01 DK053825; United States / NCI NIH HHS / CA / R21 CA116790; United States / NIDDK NIH HHS / DK / DK053825
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Ligands; 0 / Progestins; 0 / Receptors, Progesterone; 0 / Small Ubiquitin-Related Modifier Proteins; 67763-96-6 / Insulin-Like Growth Factor I; 76687-96-2 / teleocalcin; EC 2.7.- / Protein Kinases
  • [Other-IDs] NLM/ PMC2732858
  •  go-up   go-down


26. Gandhi M, Dillon LW, Pramanik S, Nikiforov YE, Wang YH: DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene; 2010 Apr 15;29(15):2272-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells.
  • Human chromosomal fragile sites are regions of the genome that are prone to DNA breakage, and are classified as common or rare, depending on their frequency in the population.
  • Common fragile sites frequently coincide with the location of genes involved in carcinogenic chromosomal translocations, suggesting their role in cancer formation.
  • However, there has been no direct evidence linking breakage at fragile sites to the formation of a cancer-specific translocation.
  • Here, we studied the involvement of fragile sites in the formation of RET/PTC rearrangements, which are frequently found in papillary thyroid carcinoma (PTC).
  • These rearrangements are commonly associated with radiation exposure; however, most of the tumors found in adults are not linked to radiation.
  • In this study, we provide structural and biochemical evidence that the RET, CCDC6 and NCOA4 genes participating in two major types of RET/PTC rearrangements, are located in common fragile sites FRA10C and FRA10G, and undergo DNA breakage after exposure to fragile site-inducing chemicals.
  • Moreover, exposure of human thyroid cells to these chemicals results in the formation of cancer-specific RET/PTC rearrangements.
  • These results provide the direct evidence for the involvement of chromosomal fragile sites in the generation of cancer-specific rearrangements in human cells.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3477-84 [12067991.001]
  • [Cites] BMC Genomics. 2009;10:59 [19183484.001]
  • [Cites] Cell. 2002 Dec 13;111(6):779-89 [12526805.001]
  • [Cites] Cancer Lett. 2003 Mar 20;192(1):1-17 [12637148.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(20):7143-51 [14517285.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):71-6 [14603443.001]
  • [Cites] Am J Hum Genet. 2004 Oct;75(4):654-60 [15309689.001]
  • [Cites] Science. 1984 Dec 7;226(4679):1199-204 [6239375.001]
  • [Cites] Hum Genet. 1985;69(3):233-7 [2579891.001]
  • [Cites] Hum Genet. 1987 Jan;75(1):75-8 [3100418.001]
  • [Cites] Am J Hum Genet. 1987 Nov;41(5):882-90 [3674017.001]
  • [Cites] Am J Hum Genet. 1988 Sep;43(3):265-73 [3137811.001]
  • [Cites] Hum Genet. 1989 Aug;83(1):45-8 [2504659.001]
  • [Cites] Genet Anal Tech Appl. 1991 Sep;8(6):161-6 [1721827.001]
  • [Cites] Cell. 1995 May 19;81(4):533-40 [7758107.001]
  • [Cites] Nucleic Acids Res. 1995 Oct 25;23(20):4202-9 [7479085.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5617-20 [7585643.001]
  • [Cites] Hum Mol Genet. 1995 Dec;4(12):2313-8 [8634704.001]
  • [Cites] Hum Mol Genet. 1997 Feb;6(2):193-203 [9063739.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4587-92 [9114034.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1690-4 [9135009.001]
  • [Cites] Environ Mol Mutagen. 1997;29(3):250-5 [9142167.001]
  • [Cites] Genomics. 1997 Jun 1;42(2):252-9 [9192845.001]
  • [Cites] Nat Genet. 1997 Nov;17(3):298-304 [9354793.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8141-6 [9653154.001]
  • [Cites] Mol Cell. 1998 May;1(6):773-81 [9660961.001]
  • [Cites] Thyroid. 1998 Jun;8(6):485-9 [9669285.001]
  • [Cites] Mol Cell. 1998 Aug;2(2):259-65 [9734364.001]
  • [Cites] Hum Mol Genet. 1999 Mar;8(3):431-7 [9949202.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2364-9 [15671095.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):99-105 [16199894.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):4-12 [16229941.001]
  • [Cites] Oncogene. 1999 Nov 4;18(46):6330-4 [10597232.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1170-5 [10720057.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(12):4420-7 [10825205.001]
  • [Cites] Chromosome Res. 2000;8(8):677-88 [11196131.001]
  • [Cites] Nucleic Acids Res. 2001 Mar 15;29(6):E33 [11239010.001]
  • [Cites] Genomics. 2001 Apr 15;73(2):149-60 [11318605.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1126-35 [16807141.001]
  • [Cites] Eur J Endocrinol. 2006 Nov;155(5):645-53 [17062879.001]
  • [Cites] Mol Cell. 2007 Aug 3;27(3):367-79 [17679088.001]
  • [Cites] J Cell Biochem. 2007 Oct 1;102(2):320-31 [17722107.001]
  • [Cites] Annu Rev Genet. 2007;41:169-92 [17608616.001]
  • [Cites] Expert Rev Mol Diagn. 2008 Jan;8(1):83-95 [18088233.001]
  • [Cites] Cell Res. 2008 Jan;18(1):134-47 [18157161.001]
  • [Cites] Cell Res. 2008 Jan;18(1):114-24 [18166980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):246-51 [18162546.001]
  • [Cites] Mod Pathol. 2008 May;21 Suppl 2:S37-43 [18437172.001]
  • [Cites] Cytogenet Genome Res. 2008;121(3-4):196-200 [18758159.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):89-97 [12086891.001]
  • (PMID = 20101222.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113863-04; United States / NCI NIH HHS / CA / R01 CA113863-04; United States / NCI NIH HHS / CA / CA113863-01A1; United States / NIGMS NIH HHS / GM / T32 GM095440; United States / NCI NIH HHS / CA / R01 CA113863-01A1; United States / NCI NIH HHS / CA / CA113863-03; United States / NCI NIH HHS / CA / R01 CA113863-02; United States / NCI NIH HHS / CA / CA113863-02; United States / NCI NIH HHS / CA / CA113863; United States / NCI NIH HHS / CA / R01 CA113863; United States / NCI NIH HHS / CA / R01 CA113863-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 38966-21-1 / Aphidicolin; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret
  • [Other-IDs] NLM/ NIHMS166296; NLM/ PMC2855398
  •  go-up   go-down


27. Ulisse S, Baldini E, Toller M, Delcros JG, Guého A, Curcio F, De Antoni E, Giacomelli L, Ambesi-Impiombato FS, Bocchini S, D'Armiento M, Arlot-Bonnemains Y: Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocr Relat Cancer; 2007 Sep;14(3):827-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its expression was found, with respect to HTU5 cells, unchanged in cells derived from a benign thyroid follicular tumor (HTU42), and significantly reduced in cell lines derived from follicular (FTC-133), papillary (B-CPAP), and anaplastic thyroid carcinomas (CAL-62 and 8305C).
  • [MeSH-major] Carcinoma / genetics. Microtubule-Associated Proteins / genetics. Microtubule-Associated Proteins / metabolism. Protein-Serine-Threonine Kinases / genetics. Protein-Serine-Threonine Kinases / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aurora Kinases. Cell Cycle / genetics. Cells, Cultured. Centrosome / drug effects. Centrosome / metabolism. Chromosome Segregation / genetics. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Piperazines / pharmacology. Ploidies. Protein Binding. Spindle Apparatus / metabolism

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Expr Patterns. 2003 May;3(2):203-11 [12711550.001]
  • [Cites] Genomics. 2003 Feb;81(2):192-201 [12620397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8102-16 [14603251.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Nov;4(11):842-54 [14625535.001]
  • [Cites] Nat Med. 2004 Mar;10(3):262-7 [14981513.001]
  • [Cites] BMC Evol Biol. 2004 Jun 18;4:16 [15207008.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5118-22 [1655245.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9004-8 [8090760.001]
  • [Cites] Thyroid. 1997 Dec;7(6):817-21 [9459622.001]
  • [Cites] Chromosoma. 1998 Dec;107(6-7):491-7 [9914382.001]
  • [Cites] Cell Growth Differ. 1999 Mar;10(3):155-62 [10099829.001]
  • [Cites] Genomics. 1999 Jun 1;58(2):165-70 [10366448.001]
  • [Cites] Oncogene. 1999 Jul 8;18(27):4032-8 [10435627.001]
  • [Cites] Trends Cell Biol. 1999 Nov;9(11):454-9 [10511710.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52175-82 [15469940.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1122-7 [15592510.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13415-23 [15687499.001]
  • [Cites] J Cell Biol. 2005 Sep 26;170(7):1057-66 [16172207.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):501-11 [12583960.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Nov;139(1):78-83 [12547166.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):78-83 [12490766.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):71-7 [12490765.001]
  • [Cites] Bioessays. 2002 Oct;24(10):915-25 [12325124.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):275-82 [16477625.001]
  • [Cites] J Cell Biol. 2005 Sep 26;170(7):1047-55 [16172205.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2631-8 [16928445.001]
  • [Cites] Mol Biol Cell. 2000 Apr;11(4):1357-67 [10749935.001]
  • [Cites] Mech Dev. 2000 Oct;97(1-2):13-26 [11025203.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14352-7 [11121038.001]
  • [Cites] Mol Genet Metab. 2001 Feb;72(2):155-63 [11161841.001]
  • [Cites] Science. 2002 Jan 18;295(5554):455-6 [11799231.001]
  • [Cites] J Cell Biol. 2002 Feb 4;156(3):437-51 [11827981.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):653-64 [11847113.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Mar;56(3):341-50 [11940046.001]
  • [Cites] Trends Cell Biol. 2002 May;12(5):222-5 [12062169.001]
  • [Cites] Oncogene. 2002 Aug 15;21(36):5619-30 [12165861.001]
  • (PMID = 17914111.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Microtubule-Associated Proteins; 0 / Piperazines; 0 / TACC3 protein, human; 639089-54-6 / VX680; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2216418
  •  go-up   go-down


28. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, Wawrowsky K, Melmed S: Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res; 2007 Nov 1;67(21):10564-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth.
  • Pituitary tumor-transforming gene (Pttg) deletion results in pituitary hypoplasia, low pituitary cell proliferation rates, and rescue of pituitary tumor development in Rb(+/-) mice.
  • As cell proliferation assessed by bromodeoxyuridine incorporation was higher in Rb(+/-)Pttg(-/-)p21(-/-) relative to Rb(+/-)Pttg(-/-) pituitary glands, p21-dependent senescence provoked by Pttg deletion may underlie pituitary hypoplasia and decreased tumor development in Rb(+/-)Pttg(-/-) mice.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cell. 1995 May 5;81(3):323-30 [7736585.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Nature. 1998 Sep 10;395(6698):125-6 [9744268.001]
  • [Cites] EMBO J. 1999 Jan 4;18(1):22-7 [9878046.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Mech Dev. 1999 Mar;81(1-2):23-35 [10330482.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):7011-9 [10490638.001]
  • [Cites] Oncogene. 1999 Sep 23;18(39):5473-6 [10498901.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51100-6 [15456744.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):25-36 [17189716.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5596-605 [17353909.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]
  • [Cites] Oncogene. 2001 Feb 22;20(8):962-71 [11314031.001]
  • [Cites] Cell. 2001 May 18;105(4):445-57 [11371342.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S27-31 [11684439.001]
  • [Cites] Curr Opin Cell Biol. 2001 Dec;13(6):748-53 [11698192.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] Nat Cell Biol. 2000 Mar;2(3):148-55 [10707085.001]
  • [Cites] Pituitary. 1999 May;1(3-4):169-79 [11081195.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10305-9 [12124396.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • [Cites] Minerva Endocrinol. 2002 Dec;27(4):277-85 [12511850.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Neurosurg Clin N Am. 2003 Jan;14(1):25-39, vi [12690977.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2814-21 [12767095.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Oncogene. 2004 Mar 15;23(11):1998-2008 [15021887.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3296-307 [15021915.001]
  • [Cites] Mol Cell. 2004 May 21;14(4):501-13 [15149599.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):792-804 [15459660.001]
  • [Cites] J Clin Invest. 1982 Nov;70(5):965-77 [6290540.001]
  • [Cites] J Cell Biol. 1997 Jan 13;136(1):1-4 [9026502.001]
  • (PMID = 17975001.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075979-09; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA75979; United States / NCI NIH HHS / CA / R01 CA075979-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 0 / Retinoblastoma Protein; 0 / Securin; 0 / Sp1 Transcription Factor; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS121885; NLM/ PMC2770267
  •  go-up   go-down


29. Guo B, Sallis RE, Greenall A, Petit MM, Jansen E, Young L, Van de Ven WJ, Sharrocks AD: The LIM domain protein LPP is a coactivator for the ETS domain transcription factor PEA3. Mol Cell Biol; 2006 Jun;26(12):4529-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PEA3 activates gene expression and is thought to play an important role in promoting tumor metastasis and also in neuronal development.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 2002 Aug 29;35(5):877-92 [12372283.001]
  • [Cites] Mol Cancer Res. 2005 Feb;3(2):63-70 [15755872.001]
  • [Cites] Biochim Biophys Acta. 2003 Feb 17;1593(2-3):115-20 [12581855.001]
  • [Cites] J Cell Sci. 2003 Apr 1;116(Pt 7):1359-66 [12615977.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Dev Biol. 2003 Jul 15;259(2):241-57 [12871699.001]
  • [Cites] Methods. 2003 Sep;31(1):67-75 [12893175.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):177-90 [14635793.001]
  • [Cites] Genes Dev. 2004 Oct 15;18(20):2518-28 [15489293.001]
  • [Cites] Anal Biochem. 1991 Feb 1;192(2):262-7 [1852137.001]
  • [Cites] Mol Cell Biol. 1994 May;14(5):3283-91 [8164681.001]
  • [Cites] Oncogene. 1995 Aug 17;11(4):771-9 [7651741.001]
  • [Cites] Mech Dev. 1999 Nov;88(2):233-6 [10534622.001]
  • [Cites] Mol Biol Cell. 2000 Jan;11(1):117-29 [10637295.001]
  • [Cites] Gene Expr. 1999;8(4):207-17 [10794523.001]
  • [Cites] Cell. 2000 May 26;101(5):485-98 [10850491.001]
  • [Cites] Adv Exp Med Biol. 2000;480:107-16 [10959416.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):965-73 [11029469.001]
  • [Cites] Biochim Biophys Acta. 2001 Apr 23;1538(2-3):260-72 [11336797.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16207-15 [11278941.001]
  • [Cites] J Biol Chem. 2001 Feb 9;276(6):4509-21 [11096072.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20108-15 [11274170.001]
  • [Cites] Curr Biol. 2001 Apr 3;11(7):503-7 [11413000.001]
  • [Cites] Mech Dev. 2001 Sep;107(1-2):105-17 [11520667.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6215-24 [11593430.001]
  • [Cites] J Virol. 2001 Dec;75(23):11791-802 [11689660.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Nov;2(11):827-37 [11715049.001]
  • [Cites] Curr Biol. 2001 Nov 13;11(22):1739-48 [11719215.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18649-57 [11901151.001]
  • [Cites] Dev Biol. 2002 Jul 15;247(2):237-50 [12086464.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24965-71 [7559624.001]
  • [Cites] Cell. 1996 Apr 5;85(1):49-60 [8620536.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1550-6 [8657129.001]
  • [Cites] Oncogene. 1996 Sep 19;13(6):1323-33 [8808707.001]
  • [Cites] Genomics. 1996 Aug 15;36(1):118-29 [8812423.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1745-54 [8895521.001]
  • [Cites] Biochem Mol Med. 1997 Aug;61(2):127-35 [9259977.001]
  • [Cites] Mol Cell Biol. 1998 Feb;18(2):710-20 [9447967.001]
  • [Cites] Trends Genet. 1998 Apr;14(4):156-62 [9594664.001]
  • [Cites] Oncogene. 1998 Jul 9;17(1):93-104 [9671318.001]
  • [Cites] Mech Dev. 1999 Jan;80(1):53-65 [10096063.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16531-6 [15542589.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1149-55 [15531578.001]
  • [Cites] BMC Cell Biol. 2005;6(1):1 [15649318.001]
  • [Cites] J Biol Chem. 2003 Jan 24;278(4):2157-68 [12441356.001]
  • (PMID = 16738319.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / ETV1 protein, human; 0 / LIM Domain Proteins; 0 / LPP protein, human; 0 / RNA, Small Interfering; 0 / Trans-Activators; 0 / Transcription Factors; 0 / transcription factor PEA3; EC 3.4.24.7 / Matrix Metalloproteinase 1
  • [Other-IDs] NLM/ PMC1489114
  •  go-up   go-down


30. Park C, Yoo JH, Kim HJ, Lim CY, Kim JW, Lee SY, Kim JH, Jang JI, Park HM: Cyclosporine treatment of perianal gland adenoma concurrent with benign prostatic hyperplasia in a dog. Can Vet J; 2010 Nov;51(11):1279-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclosporine treatment of perianal gland adenoma concurrent with benign prostatic hyperplasia in a dog.
  • The nodules were diagnosed as perianal gland adenoma based on histopathologic examination.
  • After therapy with cyclosporin A for 5 wk, the perianal masses were moderately shrunken.
  • [MeSH-major] Adenoma / veterinary. Anal Gland Neoplasms / drug therapy. Cyclosporine / therapeutic use. Dog Diseases / drug therapy. Immunosuppressive Agents / therapeutic use

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2001 Mar 5;193(5):607-20 [11238591.001]
  • [Cites] J Neurochem. 1997 Mar;68(3):1142-9 [9048760.001]
  • [Cites] Vet Dermatol. 2002 Apr;13(2):77-87 [11972891.001]
  • [Cites] J Am Vet Med Assoc. 2002 Aug 1;221(3):370-7 [12164533.001]
  • [Cites] J Am Vet Med Assoc. 2002 Apr 1;220(7):1009-16 [12420778.001]
  • [Cites] Vet Dermatol. 2003 Feb;14(1):1-9 [12603680.001]
  • [Cites] Vet Dermatol. 2003 Feb;14(1):11-22 [12603681.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Jun;284(6):C1593-603 [12734112.001]
  • [Cites] J Small Anim Pract. 2004 May;45(5):238-43 [15163050.001]
  • [Cites] Vet Rec. 1975 Dec 13;97(24):464-7 [173072.001]
  • [Cites] Cancer Res. 1977 Jul;37(7 Pt 1):2068-71 [861936.001]
  • [Cites] Aust Vet J. 2004 Nov;82(11):681-5 [15977612.001]
  • [Cites] J Am Vet Med Assoc. 2005 Jun 1;226(11):1855-63 [15934253.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Mar;46(3):782-90 [15728531.001]
  • [Cites] J Neurol. 1999 May;246(5):339-46 [10399863.001]
  • [Cites] Transplant Proc. 1998 Aug;30(5):2167-70 [9723430.001]
  • [Cites] Vet Surg. 1998 Jan-Feb;27(1):64-8 [9449179.001]
  • [Cites] J Am Vet Med Assoc. 1997 Nov 15;211(10):1249-53 [9373359.001]
  • [Cites] J Urol. 1987 Oct;138(4 Pt 2):991-5 [3656581.001]
  • [Cites] Can Vet J. 1997 Jan;38(1):39-41 [8993784.001]
  • [Cites] J Am Vet Med Assoc. 1996 Feb 15;208(4):517-9 [8603899.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2689-98 [7545467.001]
  • [Cites] Mol Cell Endocrinol. 1994 Feb;99(1):21-4 [8187957.001]
  • [Cites] Transplantation. 1992 Jan;53(1):190-5 [1310171.001]
  • [Cites] Am J Vet Res. 1988 Oct;49(10):1742-6 [3189991.001]
  • [Cites] Endocrinology. 1988 Aug;123(2):1069-74 [3396498.001]
  • [Cites] Res Vet Sci. 2006 Oct;81(2):231-6 [16427103.001]
  • [Cites] Vet Rec. 2001 May 26;148(21):662-3 [11400987.001]
  • (PMID = 21286331.001).
  • [ISSN] 0008-5286
  • [Journal-full-title] The Canadian veterinary journal = La revue vétérinaire canadienne
  • [ISO-abbreviation] Can. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  • [Other-IDs] NLM/ PMC2957039
  •  go-up   go-down


31. Hoshino A, Yee CJ, Campbell M, Woltjer RL, Townsend RL, van der Meer R, Shyr Y, Holt JT, Moses HL, Jensen RA: Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia. Int J Biol Sci; 2007;3(5):281-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia.
  • To characterize the role of BRCA1 in mammary gland development and tumor suppression, a transgenic mouse model of BRCA1 overexpression was developed.
  • Using the mouse mammary tumor virus (MMTV) promoter/enhancer, transgenic mice expressing human BRCA1 or select mutant controls were generated.
  • Morphometric analyses of mammary gland whole mount preparations were used to measure epithelial staining indices of ~35% for homozygous MMTV-BRCA1 mice and ~60% for both hemizygous and homozygous MMTV-BRCA1sv mice versus ~25% for non-transgenic mice.
  • In contrast, homozygous MMTV-BRCA1sv transgenic animals were sensitized to DMBA treatment and exhibited a very rapid onset of mammary tumor development and accelerated mortality.
  • MMTV-BRCA1 effects on mortality were restricted to DMBA-induced tumors of the mammary gland.
  • These results demonstrate in vivo roles for BRCA1 in both mammary gland development and in tumor suppression against mutagen-induced mammary gland neoplasia.
  • [MeSH-major] BRCA1 Protein / physiology. Genes, BRCA1. Mammary Glands, Animal / growth & development. Mammary Neoplasms, Experimental / genetics
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Animals. Carcinogens / toxicity. Female. Gene Expression. Gene Transfer Techniques. Mammary Tumor Virus, Mouse. Mice. Mice, Inbred Strains. Mice, Transgenic. Pregnancy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1998 Dec 17;17(24):3115-24 [9872327.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):1959-68 [9815585.001]
  • [Cites] Nat Genet. 1999 May;22(1):37-43 [10319859.001]
  • [Cites] Nature. 2000 Nov 23;408(6811):429-32 [11100717.001]
  • [Cites] Nat Struct Biol. 2001 Oct;8(10):838-42 [11573086.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):25-37 [11801721.001]
  • [Cites] Cell. 2002 Jan 25;108(2):171-82 [11832208.001]
  • [Cites] Genes Dev. 2002 Mar 1;16(5):583-93 [11877378.001]
  • [Cites] EMBO J. 2002 Jul 15;21(14):3863-72 [12110597.001]
  • [Cites] Transgenic Res. 2002 Oct;11(5):467-78 [12437078.001]
  • [Cites] Hum Mol Genet. 2003 Apr 1;12 Spec No 1:R113-23 [12668603.001]
  • [Cites] Science. 2003 Oct 24;302(5645):636-9 [14576432.001]
  • [Cites] Science. 2003 Oct 24;302(5645):639-42 [14576433.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5792-8 [15122325.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38409-14 [15229228.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] DNA. 1988 May;7(4):261-7 [3293952.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1147-55 [2161707.001]
  • [Cites] Am J Hum Genet. 1993 Apr;52(4):678-701 [8460634.001]
  • [Cites] Biotechniques. 1993 Sep;15(3):532-4, 536-7 [7692896.001]
  • [Cites] Genes Dev. 1993 Dec;7(12A):2308-17 [8253379.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1678-83 [8137281.001]
  • [Cites] Science. 1994 Oct 7;266(5182):66-71 [7545954.001]
  • [Cites] Nat Genet. 1994 Dec;8(4):387-91 [7894491.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4254-8 [7753792.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):17-26 [7550308.001]
  • [Cites] Am J Hum Genet. 1995 Dec;57(6):1457-62 [8533776.001]
  • [Cites] Genes Dev. 1995 Nov 1;9(21):2712-22 [7590247.001]
  • [Cites] Mol Biol Cell. 1995 Oct;6(10):1287-303 [8573787.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):191-4 [8563759.001]
  • [Cites] Nat Genet. 1996 Mar;12(3):298-302 [8589721.001]
  • [Cites] Hum Mol Genet. 1995 Dec;4(12):2259-64 [8634696.001]
  • [Cites] Hum Mol Genet. 1995 Dec;4(12):2265-73 [8634697.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2318-24 [8635102.001]
  • [Cites] Cell. 1996 Jun 28;85(7):1009-23 [8674108.001]
  • [Cites] Oncogene. 1996 Jun 20;12(12):2507-13 [8700509.001]
  • [Cites] Genes Dev. 1996 Jul 15;10(14):1835-43 [8698242.001]
  • [Cites] Oncogene. 1996 Aug 1;13(3):649-53 [8760307.001]
  • [Cites] Mol Cell Biol. 1997 Jan;17(1):444-52 [8972225.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):419-25 [9121124.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 1;25(11):2138-46 [9153313.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3387-400 [9407031.001]
  • [Cites] J Histochem Cytochem. 1997 Nov;45(11):1559-65 [9358857.001]
  • [Cites] Genes Dev. 1997 May 15;11(10):1226-41 [9171368.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):56-9 [9425901.001]
  • [Cites] Mol Biol Cell. 1998 Feb;9(2):421-35 [9450965.001]
  • [Cites] Oncogene. 1998 Jan 8;16(1):61-8 [9467943.001]
  • [Cites] J Histochem Cytochem. 1999 Jan;47(1):119-26 [9857219.001]
  • (PMID = 17505536.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / Carcinogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ PMC1865089
  •  go-up   go-down


32. Ren SG, Melmed S: Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretion. Endocrinology; 2006 Aug;147(8):3936-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretion.
  • Pyridoxal phosphate (PLP), a bioactive form of pyridoxine, dose-dependently (10-1000 microm) inhibited cell proliferation in rat pituitary MMQ and GH3 cells and in mouse AtT-20 cells.
  • After 4 d, MMQ cell numbers were reduced by up to 81%, GH3 cell numbers were reduced by up to 64% (P < 0.05), and AtT-20 cell numbers were reduced by up to 90%.
  • Cell proliferation rates recovered and dose-dependently reverted to control levels after PLP withdrawal.
  • After 4 d, PLP (400 and 1000 microm) decreased [3H]thymidine incorporation by up to 71% (P < 0.05).
  • PLP (400-1000 microm) reduced GH3 cell GH and prolactin secretion and AtT-20 cell ACTH secretion (adjusted for cell number) by approximately 70% after 2 d.
  • The 100 microm PLP also inhibited prolactin secretion (65%, P < 0.05) in primary rat pituitary cells treated for 2 d.
  • PLP decreased the percentage of AtT-20 and GH3 cells in S phase and increased those in G0-G1 phase.
  • Furthermore, PLP induced AtT-20 and GH3 cell apoptosis (28 vs. 6, P < 0.05; 26 vs. 3, P < 0.05, respectively) and dose-dependently reduced content of the antiapoptosis gene Bcl-2.
  • These results indicate that pharmacological doses of PLP inhibit pituitary cell proliferation and hormone secretion, in part mediated through PLP-induced cell-cycle arrest and apoptosis.
  • Pyridoxine may therefore be appropriate for testing as a relatively safe drug for adjuvant treatment of hormone-secreting pituitary adenomas.

  • MedlinePlus Health Information. consumer health - B Vitamins.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1987 May;78(5):951-9 [3472003.001]
  • [Cites] Am J Clin Nutr. 1987 Oct;46(4):659-64 [3499066.001]
  • [Cites] Anticancer Res. 1988 Nov-Dec;8(6):1313-8 [3218963.001]
  • [Cites] J Clin Lab Anal. 1989;3(2):95-100 [2732845.001]
  • [Cites] J Biol Chem. 1990 Jul 25;265(21):12424-33 [2373699.001]
  • [Cites] J Biol Chem. 1992 Feb 25;267(6):3819-24 [1310983.001]
  • [Cites] J Nutr. 1995 Sep;125(9):2370-8 [7666255.001]
  • [Cites] Recent Prog Horm Res. 1996;51:189-215; discussion 215-6 [8701079.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):789-98 [9045884.001]
  • [Cites] Endocr Rev. 1997 Apr;18(2):206-28 [9101137.001]
  • [Cites] Nutr Cancer. 1997;28(2):206-11 [9290129.001]
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1275-83 [9543156.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):684-92 [15870439.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):265-9 [15944799.001]
  • [Cites] J Nutr. 2001 Aug;131(8):2204-7 [11481418.001]
  • [Cites] Endocrinology. 2001 Sep;142(9):3756-63 [11517151.001]
  • [Cites] Nutr Cancer. 2000;38(2):281-6 [11525607.001]
  • [Cites] Neoplasma. 2001;48(4):307-12 [11712684.001]
  • [Cites] J Steroid Biochem. 1986 Sep;25(3):359-65 [3773514.001]
  • [Cites] Nutr Cancer. 1985;7(1-2):43-52 [4070008.001]
  • [Cites] Neurology. 1985 Oct;35(10):1466-8 [2993949.001]
  • [Cites] JAMA. 2002 Jun 19;287(23):3116-26 [12069675.001]
  • [Cites] Urol Clin North Am. 2002 Feb;29(1):157-68 [12109342.001]
  • [Cites] J Nutr. 2002 Nov;132(11):3308-13 [12421844.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):499-508 [12579301.001]
  • [Cites] Nutr Cancer. 2002;43(2):152-8 [12588695.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 5;95(5):373-80 [12618502.001]
  • [Cites] Biochim Biophys Acta. 2003 Apr 11;1647(1-2):127-30 [12686121.001]
  • [Cites] Cancer Causes Control. 2003 Jun;14(5):477-84 [12946043.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1271-2 [14652294.001]
  • [Cites] Am J Clin Nutr. 2004 May;79(5):805-11 [15113718.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):819-23 [15492851.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Feb;40(2):256-9 [1117978.001]
  • [Cites] J Clin Endocrinol Metab. 1976 Mar;42(3):603-6 [1254699.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Jun;44(6):1197-9 [559690.001]
  • [Cites] Biomedicine. 1977 Jul;27(6):219-22 [20170.001]
  • [Cites] Biomedicine. 1978 Feb;29(1):13-5 [667280.001]
  • [Cites] Acta Endocrinol (Copenh). 1978 Oct;89(2):217-20 [358720.001]
  • [Cites] J Endocrinol Invest. 1979 Apr-Jun;2(2):117-24 [573769.001]
  • [Cites] J Clin Invest. 1980 Oct;66(4):688-95 [7419716.001]
  • [Cites] J Clin Endocrinol Metab. 1982 Apr;54(4):872-5 [6801073.001]
  • [Cites] N Engl J Med. 1982 Aug 12;307(7):444-5 [7088124.001]
  • [Cites] J Inorg Biochem. 1982 Nov;17(3):185-203 [6757388.001]
  • [Cites] J Clin Endocrinol Metab. 1978 Sep;47(3):689-90 [263321.001]
  • [Cites] N Engl J Med. 1983 Aug 25;309(8):445-8 [6308447.001]
  • [Cites] Horm Metab Res. 1985 Jan;17(1):46-7 [3967846.001]
  • (PMID = 16690808.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA 75979
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 12001-76-2 / Vitamin B Complex; 5V5IOJ8338 / Pyridoxal Phosphate; 9002-62-4 / Prolactin; 9002-72-6 / Growth Hormone
  • [Other-IDs] NLM/ NIHMS10630; NLM/ PMC1513048
  •  go-up   go-down


33. Veuger SJ, Hunter JE, Durkacz BW: Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance. Oncogene; 2009 Feb 12;28(6):832-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / metabolism. NF-kappa B / metabolism. Poly(ADP-ribose) Polymerases / metabolism. Radiation, Ionizing. Transcription Factor RelA / metabolism
  • [MeSH-minor] Active Transport, Cell Nucleus. Apoptosis. Azulenes / pharmacology. Benzodiazepines / pharmacology. Caspases / metabolism. Cell Line, Tumor. Enzyme Inhibitors / pharmacology. Gene Expression Regulation, Neoplastic / radiation effects. Humans. Models, Biological. Poly(ADP-ribose) Polymerase Inhibitors. RNA, Small Interfering / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 22;18(49):6910-24 [10602466.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6817-30 [17072330.001]
  • [Cites] Oncogene. 2000 Aug 24;19(36):4159-69 [10962577.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6557-62 [11118032.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):557-63 [11159825.001]
  • [Cites] Trends Biochem Sci. 2001 Mar;26(3):174-9 [11246023.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):183-93 [11316563.001]
  • [Cites] Apoptosis. 2001 Aug;6(4):253-61 [11445667.001]
  • [Cites] Ann Oncol. 2001 Jun;12(6):799-805 [11484955.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10386-91 [11517301.001]
  • [Cites] Semin Radiat Oncol. 2001 Oct;11(4):346-51 [11677659.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):45588-97 [11590148.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):47664-70 [11577079.001]
  • [Cites] Cell. 2002 Apr;109 Suppl:S81-96 [11983155.001]
  • [Cites] J Med Chem. 2003 Jan 16;46(2):210-3 [12519059.001]
  • [Cites] J Neurochem. 2003 Apr;85(2):306-17 [12675907.001]
  • [Cites] Breast Cancer Res Treat. 2003 May;79(1):37-46 [12779080.001]
  • [Cites] Cell. 2003 Jun 13;113(6):677-83 [12809599.001]
  • [Cites] Oncogene. 2003 Sep 1;22(37):5813-27 [12947388.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):6887-900 [12972607.001]
  • [Cites] Biochem Pharmacol. 2003 Oct 1;66(7):1189-98 [14505798.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6008-15 [14522929.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6815-24 [14583479.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):215-23 [14635796.001]
  • [Cites] Free Radic Res. 2003 Sep;37(9):967-73 [14670004.001]
  • [Cites] J Natl Cancer Inst. 2004 Jan 7;96(1):56-67 [14709739.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):410-9 [14751510.001]
  • [Cites] Nucleic Acids Res. 2004;32(2):757-66 [14762203.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5405-12 [14645242.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10137-42 [15220474.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):42774-86 [15302869.001]
  • [Cites] J Clin Invest. 1991 Aug;88(2):691-5 [1864978.001]
  • [Cites] Anal Biochem. 1991 Mar 2;193(2):236-9 [1908195.001]
  • [Cites] Mol Cell Biochem. 1994 Sep;138(1-2):53-9 [7898476.001]
  • [Cites] Science. 1996 Nov 1;274(5288):782-4 [8864118.001]
  • [Cites] Science. 1996 Nov 1;274(5288):784-7 [8864119.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3629-39 [9199297.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2952-60 [9399940.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1680-3 [9733516.001]
  • [Cites] Int J Radiat Biol. 1998 Nov;74(5):617-24 [9848280.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3485-95 [10207072.001]
  • [Cites] EMBO J. 1999 Aug 16;18(16):4446-54 [10449410.001]
  • [Cites] Biol Chem. 1999 Jul-Aug;380(7-8):953-9 [10494847.001]
  • [Cites] EMBO J. 1999 Oct 1;18(19):5242-51 [10508158.001]
  • [Cites] J Surg Res. 2005 Jan;123(1):158-69 [15652965.001]
  • [Cites] EMBO J. 2005 Feb 9;24(3):645-55 [15650747.001]
  • [Cites] Curr Med Chem. 2005;12(3):357-74 [15723624.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):1130-44 [15743683.001]
  • [Cites] J Biol Chem. 2005 Dec 9;280(49):40450-64 [16204234.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5744-56 [16740713.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6717-30 [17072324.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6938-47 [10602468.001]
  • (PMID = 19060926.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A8048; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1-(4-dimethylaminomethylphenyl)-8,9-dihydro-7H-2,7,9a-benzo(cd)azulen-6-one; 0 / Azulenes; 0 / Enzyme Inhibitors; 0 / NF-kappa B; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 0 / RELA protein, human; 0 / RNA, Small Interfering; 0 / Transcription Factor RelA; 12794-10-4 / Benzodiazepines; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2642763; NLM/ UKMS2799
  •  go-up   go-down


34. Stuelten CH, Busch JI, Tang B, Flanders KC, Oshima A, Sutton E, Karpova TS, Roberts AB, Wakefield LM, Niederhuber JE: Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One; 2010;5(3):e9832
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer.
  • When a cancer cell metastasizes, it first will be exposed to cancer associated fibroblasts in the immediate tumor microenvironment and then to normal fibroblasts as it traverses the underlying connective tissue towards the bloodstream.
  • The interaction of tumor cells with stromal fibroblasts influences tumor biology by mechanisms that are not yet fully understood.
  • Transient treatment of MCF10CA1a cells with CoCM in vitro accelerated tumor growth at orthotopic sites in vivo, and resulted in an expanded pattern of metastatic engraftment.
  • The effects of CoCM on MCF10CA1a cells were dependent on small amounts of active TGF-beta1 secreted by fibroblasts under the influence of the tumor cells, and required intact ALK5-, p38-, and JNK signaling in the tumor cells.
  • In conclusion, these results demonstrate that transient interactions between tumor cells and normal fibroblasts can modify the acellular component of the local microenvironment such that it induces long-lasting increases in tumorigenicity and alters the metastatic pattern of the cancer cells in vivo.
  • [MeSH-major] Breast Neoplasms / pathology. Fibroblasts / cytology. Neoplasms / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement. Coculture Techniques. Culture Media, Conditioned / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Models, Biological. Neoplasm Metastasis. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 2005 Oct;15(5):329-41 [15970443.001]
  • [Cites] Oncogene. 2005 Jul 28;24(32):5053-68 [15856015.001]
  • [Cites] Cell Cycle. 2005 Aug;4(8):1022-5 [16082203.001]
  • [Cites] Oncogene. 2005 Nov 17;24(51):7624-9 [16007121.001]
  • [Cites] Expert Opin Ther Targets. 2005 Dec;9(6):1217-33 [16300472.001]
  • [Cites] Cell Mol Life Sci. 2006 Feb;63(4):449-68 [16416030.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:383-8 [16869775.001]
  • [Cites] Immunol Invest. 2006;35(3-4):297-325 [16916756.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:287-309 [16824016.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4244-53 [17483336.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):851-61 [17486574.001]
  • [Cites] J Cell Biochem. 2007 Oct 15;102(3):593-608 [17729308.001]
  • [Cites] Biotechniques. 2007 Sep;43(3):289-90, 292, 294 [17907571.001]
  • [Cites] Clin Transl Oncol. 2008 Jan;10(1):14-9 [18208788.001]
  • [Cites] Front Biosci. 2008;13:3975-85 [18508491.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7278-82 [18794114.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):415-32 [12882526.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):1116-24 [14523048.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8284-92 [14678987.001]
  • [Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):822-32 [14970860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4523-30 [15231662.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7678-82 [2217201.001]
  • [Cites] Semin Cancer Biol. 1990 Apr;1(2):99-106 [2103492.001]
  • [Cites] EXS. 1993;65:301-10 [7678533.001]
  • [Cites] Endocrinology. 1994 Mar;134(3):1039-45 [8119140.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11236-40 [7972041.001]
  • [Cites] Science. 1995 Dec 22;270(5244):2008-11 [8533096.001]
  • [Cites] Anal Biochem. 1997 Apr 5;247(1):45-51 [9126369.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):169-78 [11252892.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Curr Opin Genet Dev. 2002 Feb;12(1):22-9 [11790550.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):331-9 [11832448.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):1057-68 [11891202.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):859-67 [12373600.001]
  • [Cites] Cell. 2005 Feb 25;120(4):513-22 [15734683.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] J Cell Sci. 2005 May 15;118(Pt 10):2143-53 [15855236.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5278-83 [15958574.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R402-10 [15987445.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):1197-205 [16002723.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):241-54 [16169468.001]
  • (PMID = 20352126.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2843748
  •  go-up   go-down


35. Larson PS, Schlechter BL, King CL, Yang Q, Glass CN, Mack C, Pistey R, de Las Morenas A, Rosenberg CL: CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer; 2008 Mar 06;8:68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer.
  • Decreased CDKN1C was not clearly associated with tumor grade, histology, ER, PR or HER2 status.
  • Thus, CDKN1C may be a breast cancer tumor suppressor.


36. Richardson AD, Yang C, Osterman A, Smith JW: Central carbon metabolism in the progression of mammary carcinoma. Breast Cancer Res Treat; 2008 Jul;110(2):297-307
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is a growing belief that the metabolic program of breast tumor cells could be a therapeutic target.
  • Yet, without detailed information on central carbon metabolism in breast tumors it is impossible to know which metabolic pathways to target, and how their inhibition might influence different stages of breast tumor progression.
  • Here we perform the first comprehensive profiling of central metabolism in the MCF10 model of mammary carcinoma, where the steps of breast tumor progression (transformation, tumorigenicity and metastasis) can all be examined in the context of the same genetic background.
  • The de novo synthesis of glycine increased upon transformation as well as at each subsequent step of breast tumor cell progression.
  • Interestingly, the major metabolic shift in metastatic cells is a large increase in the de novo synthesis of proline.
  • This work provides the first comprehensive view of changes to central metabolism as a result of breast tumor progression.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2004 Aug;18(11):1303-5 [15180958.001]
  • [Cites] Pac Symp Biocomput. 2007;:181-92 [17990491.001]
  • [Cites] Nutrition. 2000 Mar;16(3):202-8 [10705076.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1088-95 [11459870.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45358-66 [11567032.001]
  • [Cites] Annu Rev Med. 2002;53:89-112 [11818465.001]
  • [Cites] J Biol Chem. 2002 Jun 28;277(26):23111-5 [11943784.001]
  • [Cites] Exp Cell Res. 2003 Jan 15;282(2):132-7 [12531699.001]
  • [Cites] Anal Biochem. 2003 Feb 1;313(1):145-54 [12576070.001]
  • [Cites] Proteomics. 2003 Jul;3(7):1256-69 [12872226.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4459-68 [12881702.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):459-65 [14697210.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2004;44:239-67 [14744246.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91 [14973383.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2070-5 [15026345.001]
  • [Cites] J Biol Chem. 1990 Aug 15;265(23):13641-9 [2380179.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Mol Carcinog. 1991;4(1):25-35 [2009132.001]
  • [Cites] Eye (Lond). 1992;6 ( Pt 4):416-9 [1478318.001]
  • [Cites] Am J Physiol. 1994 Mar;266(3 Pt 1):E372-83 [8166257.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4293-6 [7671238.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 1):E843-51 [9612242.001]
  • [Cites] Z Naturforsch C. 1998 Mar-Apr;53(3-4):279-85 [9618942.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):77-85 [15652751.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5512-5 [15994921.001]
  • [Cites] J Biol Chem. 2005 Jul 8;280(27):25339-49 [15851470.001]
  • [Cites] Hum Mol Genet. 2005 Aug 1;14(15):2231-9 [15987702.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(2):177-86 [16319984.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):5977-80 [16778164.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):358-65 [16778563.001]
  • [Cites] Sci STKE. 2006 Jul 31;2006(346):re7 [16885148.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8927-30 [16982728.001]
  • [Cites] Metab Eng. 2006 Nov;8(6):639-52 [16904360.001]
  • [Cites] J Nutr. 2004 Nov;134(11):3201S-3204S [15514307.001]
  • (PMID = 17879159.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA108959; United States / NCI NIH HHS / CA / R01 CA108959; United States / NCI NIH HHS / CA / P30 CA030199; United States / NIAID NIH HHS / AI / R01 AI059146; United States / NCRR NIH HHS / RR / U54 RR020843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fatty Acids; 0 / Lactates; 7440-44-0 / Carbon; 9DLQ4CIU6V / Proline; IY9XDZ35W2 / Glucose
  • [Other-IDs] NLM/ PMC2440942
  •  go-up   go-down


37. Jotwani AC, Gralow JR: Early detection of breast cancer: new biomarker tests on the horizon? Mol Diagn Ther; 2009 Dec 01;13(6):349-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When cancer is detected early, patients live longer, require less extensive treatment, and in general fare better than patients with more advanced disease.
  • Breast cancer screening through mammography has shown significant mortality reduction in clinical trials through the early detection of disease.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Early Detection of Cancer / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 2009 Mar;135(3):329-37 [19009309.001]
  • [Cites] Pathobiology. 2008;75(2):149-52 [18544970.001]
  • [Cites] BMC Cancer. 2008 Mar 19;8:75 [18366688.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1518-28 [18318472.001]
  • [Cites] Mol Cancer Ther. 2008 Mar;7(3):449-54 [18319334.001]
  • [Cites] Nat Genet. 2009 May;41(5):585-90 [19330027.001]
  • [Cites] Biochim Biophys Acta. 2007 Jun;1770(6):847-56 [17368950.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1073-80 [903989.001]
  • [Cites] Proteomics Clin Appl. 2008 Oct 1;2(10-11):1386-1402 [20976028.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001877 [17054145.001]
  • [Cites] Ann Intern Med. 2002 Sep 3;137(5 Part 1):347-60 [12204020.001]
  • [Cites] Anal Bioanal Chem. 2008 Feb;390(4):1039-50 [17694298.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1791-8 [11734595.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1481-9 [18311905.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:57-66 [9422089.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):243-52 [12671663.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2410-4 [11489820.001]
  • [Cites] Pathol Res Pract. 1988 Jun;183(3):271-6 [2843840.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5091-7 [17033037.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):261-70 [16395408.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):950-5 [17507621.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):812-26 [19103723.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):130-41 [1536131.001]
  • [Cites] Nat Genet. 2009 May;41(5):579-84 [19330030.001]
  • [Cites] Br J Cancer. 1999 Oct;81(4):702-4 [10574259.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1388-94 [18311901.001]
  • [Cites] Cancer Res. 2009 Jun 15;69(12):5133-41 [19491255.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4943-8 [17699874.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(10):1556-63 [17532207.001]
  • [Cites] Breast Cancer Res Treat. 2009 Apr;114(3):599-605 [18465220.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Ann Pathol. 2006 Sep;26(4):257-66 [17128152.001]
  • [Cites] J Proteome Res. 2007 Oct;6(10):3962-75 [17711321.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jul;98(1):63-70 [16685591.001]
  • [Cites] J Proteome Res. 2008 Aug;7(8):3613-8 [18624399.001]
  • [Cites] Clin Sci (Lond). 1997 Oct;93(4):287-93 [9404219.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):185-213 [15947097.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2734-8 [18636293.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):324-8 [15734953.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):215-25 [15652811.001]
  • [Cites] J Cell Sci. 1993 Jun;105 ( Pt 2):533-40 [8408282.001]
  • [Cites] J Natl Cancer Inst. 2008 Jul 16;100(14):1037-41 [18612136.001]
  • [Cites] Stat Methods Med Res. 2004 Dec;13(6):421-42 [15587432.001]
  • [Cites] Mol Diagn. 2003;7(1):49-55 [14529321.001]
  • [Cites] Recent Results Cancer Res. 1996;140:101-13 [8787054.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3363-7 [9363867.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):30-2 [16395401.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):313-25 [18086794.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):51-63 [18060046.001]
  • [Cites] Biol Res Nurs. 2007 Oct;9(2):108-16 [17909163.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 [18663219.001]
  • [Cites] Acad Radiol. 2008 Dec;15(12):1590-5 [19000876.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):1949-57 [18098283.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1490-9 [18311903.001]
  • (PMID = 19925032.001).
  • [ISSN] 1179-2000
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 60
  •  go-up   go-down


38. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther; 2006 Jun;5(6):674-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.
  • The hedgehog pathway regulates epithelial-mesenchymal interactions, differentiation, proliferation and survival during development.
  • Stimulation of hedgehog signaling induces carcinogenesis or promotes cell survival in cancers of multiple organs.
  • Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.
  • Hedgehog ligands were expressed at higher levels in some cancer epithelial cell lines compared to noncancerous epithelial cells.
  • Correspondingly, expression of GLI1, a transcription factor and transcriptional product of hedgehog signaling, was increased 8-fold in cancer epithelial cell lines; however, PTCH1, also a transcriptional target of hedgehog signaling in many cell types, was not increased.
  • GLI1 protein and mRNA, and PTCH1 and sonic hedgehog (SHH) proteins were elevated in 3 of 10 breast cancers; however, PTCH1 transcripts were not consistently increased.
  • Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.
  • However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.
  • Treatment with sonic hedgehog ligand diminished the cyclopamine-induced reduction in GLI-dependent promoter activity in MCF10AT and MDA-MB-435 and viability of MDA-MB-435.
  • These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.
  • Determination as to whether the increase in GLI1 and SHH expression in breast cancer indicates a significant increase in hedgehog signaling will require further evaluation.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]
  • [Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]
  • [Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]
  • [Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]
  • [Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]
  • [Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]
  • [Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • (PMID = 16855373.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635
  •  go-up   go-down


39. Domenech M, Yu H, Warrick J, Badders NM, Meyvantsson I, Alexander CM, Beebe DJ: Cellular observations enabled by microculture: paracrine signaling and population demographics. Integr Biol (Camb); 2009 Mar;1(3):267-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this example the data support the hypothesis that a growth promoting subpopulation of cells exists in the mouse mammary gland.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stem Cell Rev. 2007 Jun;3(2):137-46 [17873346.001]
  • [Cites] Nat Protoc. 2007;2(7):1782-8 [17641645.001]
  • [Cites] Lab Chip. 2008 May;8(5):717-24 [18432341.001]
  • [Cites] Lab Chip. 2008 Jun;8(6):860-4 [18497902.001]
  • [Cites] Biotechniques. 2008 Sep;45(3):321-5 [18778256.001]
  • [Cites] Integr Biol (Camb). 2009 Feb;1(2):182-95 [20023802.001]
  • [Cites] J Clin Invest. 2001 May;107(10):1235-44 [11375413.001]
  • [Cites] Dev Cell. 2002 Aug;3(2):245-57 [12194855.001]
  • [Cites] Oncogene. 2003 Dec 18;22(58):9243-53 [14681683.001]
  • [Cites] Lab Chip. 2004 Jun;4(3):186-90 [15159776.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 17;84(12):951-7 [1378502.001]
  • [Cites] Science. 1997 May 30;276(5317):1425-8 [9162012.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1627-36 [9816342.001]
  • [Cites] Dev Biol. 1999 Oct 1;214(1):128-38 [10491262.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Lab Chip. 2005 Oct;5(10):1089-95 [16175265.001]
  • [Cites] Nature. 2005 Sep 29;437(7059):648-55 [16193039.001]
  • [Cites] Nat Cell Biol. 2005 Oct;7(10):947-53 [16179950.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] Lab Chip. 2006 Mar;6(3):389-93 [16511622.001]
  • [Cites] J Mol Histol. 2006 May;37(3-4):171-7 [16977429.001]
  • [Cites] Lab Chip. 2006 Dec;6(12):1484-6 [17203151.001]
  • [Cites] Lab Chip. 2007 Mar;7(3):388-91 [17330172.001]
  • [Cites] Lab Chip. 2007 Jun;7(6):726-30 [17538714.001]
  • [Cites] Nano Lett. 2007 Dec;7(12):3759-65 [17979310.001]
  • (PMID = 20011455.001).
  • [ISSN] 1757-9708
  • [Journal-full-title] Integrative biology : quantitative biosciences from nano to macro
  • [ISO-abbreviation] Integr Biol (Camb)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K25 CA104162-05; United States / NLM NIH HHS / LM / 5T15LM007359; United States / NCI NIH HHS / CA / K25 CA104162; United States / NCI NIH HHS / CA / CA104162-05; United States / NLM NIH HHS / LM / T15 LM007359
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS156149; NLM/ PMC2791414
  •  go-up   go-down


40. Polton G: Anal sac gland carcinoma in cocker spaniels. Vet Rec; 2008 Nov 15;163(20):608
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac gland carcinoma in cocker spaniels.
  • [MeSH-major] Anal Gland Neoplasms / genetics. Anal Sacs. Dog Diseases / genetics
  • [MeSH-minor] Animals. Blood Specimen Collection / veterinary. Breeding. Dogs. Genetic Predisposition to Disease. Genotype. Research

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011255.001).
  • [ISSN] 0042-4900
  • [Journal-full-title] The Veterinary record
  • [ISO-abbreviation] Vet. Rec.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


41. Amir S, Margaryan NV, Odero-Marah V, Khalkhali-Ellis Z, Hendrix MJ: Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells. Cancer Biol Ther; 2005 Apr;4(4):400-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Maspin, a unique serine proteinase inhibitor (serpin), plays a key role in mammary gland development and is silenced during breast cancer progression.
  • Maspin has been shown to inhibit tumor cell motility and invasion in cell culture, as well as growth and metastasis in animal models.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):1-22 [9212216.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Blood. 1998 May 1;91(9):3300-7 [9558386.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5863-70 [10606224.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8676-82 [11751384.001]
  • [Cites] Med Res Rev. 2001 Mar;21(2):146-70 [11223863.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):400-5 [11196194.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):2018-24 [11064360.001]
  • [Cites] Gene Ther. 1998 Aug;5(8):1105-13 [10326034.001]
  • [Cites] Int J Cancer. 1999 Feb 9;80(4):617-23 [9935166.001]
  • [Cites] Nat Med. 2000 Feb;6(2):196-9 [10655109.001]
  • [Cites] Thromb Haemost. 1999 Sep;82 Suppl 1:19-22 [10695480.001]
  • [Cites] Nat Med. 2000 Apr;6(4):374-6 [10742136.001]
  • [Cites] Cancer Gene Ther. 2000 Feb;7(2):292-9 [10770639.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2775-83 [11023511.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1194-7 [12142372.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4478-83 [12154058.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7824-30 [12420219.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1138-43 [12615733.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1411-7 [12707024.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4):398-403 [14508113.001]
  • [Cites] Anal Biochem. 1980 Feb;102(1):196-202 [7188842.001]
  • [Cites] Biochemistry. 1982 Dec 7;21(25):6410-5 [6891264.001]
  • [Cites] Cell. 1983 Dec;35(3 Pt 2):611-9 [6418388.001]
  • [Cites] Cancer Lett. 1987 Dec;38(1-2):137-47 [3690504.001]
  • [Cites] Blood. 1988 Jun;71(6):1703-6 [3259442.001]
  • [Cites] J Biol Chem. 1988 Aug 15;263(23):11189-95 [2969891.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(24):9533-7 [3200838.001]
  • [Cites] J Biol Chem. 1990 Jun 15;265(17):9904-8 [2161846.001]
  • [Cites] J Clin Invest. 1991 Oct;88(4):1067-72 [1833420.001]
  • [Cites] Physiol Rev. 1993 Jan;73(1):161-95 [8419965.001]
  • [Cites] J Biol Chem. 1993 Mar 5;268(7):4806-13 [8444857.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5021-5 [8389464.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3109-17 [8391387.001]
  • [Cites] Science. 1994 Jan 28;263(5146):526-9 [8290962.001]
  • [Cites] Cancer Metastasis Rev. 1994 Jun;13(2):139-68 [7923547.001]
  • [Cites] J Biol Chem. 1994 Dec 9;269(49):30988-93 [7983035.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;213 ( Pt 1):51-64 [8814994.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11669-74 [8876194.001]
  • [Cites] Clin Exp Metastasis. 1997 Jan;15(1):19-25 [9009102.001]
  • [Cites] Biol Chem. 1997 Mar-Apr;378(3-4):231-7 [9165076.001]
  • [CommentIn] Cancer Biol Ther. 2005 Sep;4(9):1033-5 [16123583.001]
  • (PMID = 15846059.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075681; United States / NCI NIH HHS / CA / R01 CA075681-10; United States / NCI NIH HHS / CA / CA 75681
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; 0 / SERPIN-B5; 0 / Serpins; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS323567; NLM/ PMC3175738
  •  go-up   go-down


42. Tampi C, Lotwala V, Lakdawala M, Coelho K: Retrorectal cyst hamartoma (tailgut cyst) with malignant transformation. Gynecol Oncol; 2007 Apr;105(1):266-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It develops from post anal foetal gut remnants, present anterior to the sacrum and posterior to the rectum.
  • This malformative lesion should be distinguished from teratomas, mullerian cysts, anal gland cysts and duplication cysts of the rectum.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Transformation, Neoplastic / pathology. Cysts / pathology. Hamartoma / pathology. Rectal Diseases / pathology. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17303225.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Martins AM, Vasques-Peyser A, Torres LN, Matera JM, Dagli ML, Guerra JL: Retrospective--systematic study and quantitative analysis of cellular proliferation and apoptosis in normal, hyperplastic and neoplastic perianal glands in dogs. Vet Comp Oncol; 2008 Jun;6(2):71-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective--systematic study and quantitative analysis of cellular proliferation and apoptosis in normal, hyperplastic and neoplastic perianal glands in dogs.
  • Neoplasms in the perianal region are frequently diagnosed in dogs.
  • In this study, 240 neoplasms of the perianal glands of dogs were retrieved from the Department of Pathology archives of the Faculty of Veterinary Medicine and Zootechny of University of São Paulo (FMVZ/USP), from 1984 to 2004.
  • These results show up the importance of studying cell proliferation and apoptosis to understand the carcinogenesis of dog perianal gland.
  • [MeSH-major] Anal Gland Neoplasms / pathology. Apoptosis. Dog Diseases / pathology. Hyperplasia / veterinary. Perianal Glands / cytology. Proliferating Cell Nuclear Antigen / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178666.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


44. Stone N, Hart Prieto MC, Crow P, Uff J, Ritchie AW: The use of Raman spectroscopy to provide an estimation of the gross biochemistry associated with urological pathologies. Anal Bioanal Chem; 2007 Mar;387(5):1657-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have shown for the first time that we are able to utilise Raman spectroscopy in determining the biochemical basis for the different pathologies within the bladder and prostate gland.
  • In this way we can achieve a better understanding of disease processes such as carcinogenesis.
  • This could have major implications in the future of the diagnosis of disease within the bladder and the prostate gland.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / metabolism. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Diagnosis, Computer-Assisted / methods. Female. Humans. Male. Spectrum Analysis, Raman / methods. Urologic Neoplasms / diagnosis. Urologic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123068.001).
  • [ISSN] 1618-2642
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / CSA/03/07/017
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


45. Kirillov V, Akimova L: Regression analysis of the initial karyometric data on tumor cells in ductal carcinoma and fibroadenoma of the mammary gland. Anal Quant Cytol Histol; 2010 Apr;32(2):102-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression analysis of the initial karyometric data on tumor cells in ductal carcinoma and fibroadenoma of the mammary gland.
  • OBJECTIVE: To reveal the differences in the parameters of the second order regression curve with a cluster of experimental points on scattergrams showing the dependence of the perimeter on the area of tumor cell nuclei between ductal carcinoma and fibroadenoma of the mammary gland.
  • STUDY DESIGN: Punctate smears taken from patients with ductal carcinoma and fibroadenoma of the mammary gland with coincident histologic and cytologic conclusion were studied and selected.
  • Karyometry of tumor cells was performed with the help of a semiautomatic computer analyzer of digital images.
  • RESULTS: It has been shown that the cluster of experimental points on scattergrams showing the dependence of the perimeter on the area of tumor cell nuclei can be well described by a second order regression curve, which is a parabola.
  • The differences in parabola parameters (coefficients of the parabola equation) characterizing the population of tumor cells in ductal carcinoma and fibroadenoma of the mammary gland were revealed.
  • CONCLUSION: Parameters of the regression curve to a cluster of experimental points on scattergrams showing the dependence of the perimeter on the area of tumor cell nuclei can be used as an additional diagnostic criterion for breast cancer.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701078.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Dahse R, Kromeyer-Hauschild K, Berndt A, Kosmehl H: No incidence of BRAF mutations in salivary gland carcinomas--implications for anti-EGFR therapies. J Biomed Biotechnol; 2009;2009:501736
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No incidence of BRAF mutations in salivary gland carcinomas--implications for anti-EGFR therapies.
  • We designed an allele-specific PCR and screened 65 salivary gland carcinoma (SGC) of the main histopathological types for the BRAF V600E mutation.
  • [MeSH-major] Proto-Oncogene Proteins B-raf / genetics. Salivary Gland Neoplasms / genetics


47. Emms SG: Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy. Aust Vet J; 2005 Jun;83(6):340-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy.
  • A retrospective study of anal sac tumours without pulmonary metastases, from the author's clinical records for the period July 1989 to July 2002, was conducted to establish the response to treatment with surgery and melphalan chemotherapy.
  • Of 21 dogs with tumours of the anal sacs 19 had apocrine gland adenocarcinomas of anal sac origin, one had a benign papillary cystadenoma and another had a malignant melanoma.
  • Two of the 19 dogs had bilateral anal sac adenocarcinomas.
  • Ten of the 19 dogs with apocrine gland adenocarcinomas of anal sac origin had sublumbar lymphadenopathy.
  • Fourteen dogs with apocrine gland adenocarcinomas of anal sac origin were treated by surgical cytoreduction and chemotherapy with melphalan.
  • Cytoreduction was by local excision of the anal sac in all 14 dogs and concurrent removal of the sublumbar retroperitoneal lymph nodes in the seven dogs with regional lymph node metastases.
  • The median survival time of dogs with sublumbar nodal metastasis was 20 months and for dogs with tumour localised to the anal sac the median survival time was 29.3 months.
  • This study suggests there is a role for melphalan in the treatment of dogs with anal sac adenocarcinoma when combined with cytoreductive surgery, with treatment survival times and the local recurrence rate of the primary tumour comparing favourably with previously published treatment regimes.
  • [MeSH-major] Anal Gland Neoplasms / epidemiology. Anal Sacs. Dog Diseases / epidemiology
  • [MeSH-minor] Adenocarcinoma / veterinary. Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cystadenoma, Papillary / veterinary. Dogs. Female. Male. Melanoma / veterinary. Neoplasm Metastasis. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Victoria / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986909.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


48. Brown HM, Wilkinson EJ: Cytology of secondary vulvar Paget's disease of urothelial origin: a case report. Acta Cytol; 2005 Jan-Feb;49(1):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of secondary vulvar Paget's disease of urothelial origin: a case report.
  • BACKGROUND: Primary cutaneous Paget's disease of the vulva is an intraepithelial adenocarcinoma most likely arising from a cutaneous stem cell with sweat gland epithelial differentiation or can be of sweat gland origin.
  • Primary vulvar Paget's disease, however, can be mimicked by an internal noncutaneous neoplasm htat has extended to secondarily involve the vulva.
  • Most commonly, this is due to an anal or rectal adenocarcinoma or a urothelial carcinoma.
  • CASE: An 81-year-old woman with a past history of urothelial carcinoma in situ of the bladder presented severalyears subsequent to treatment for bladder cancer with extensive vulvar and vaginal disease, clinically interpreted as primary vulvar Paget's disease involving the vagina.
  • Subsequent investigation of her bladder showed recurrent urothelial carcinoma in situ with extensive spread to the vagina and vulva, simulating primary cutaneous vulvar Paget's disease.
  • CONCLUSION: It is important to recognize secondary vulvar Paget's disease, although uncommon, because of the difference in therapy for primary and secondary vulvar Paget's disease.
  • Certain cytologic characteristics in a vaginal or vulvar smear in a patient with suspected vulvar Paget's disease may aid in distinguishing them.
  • [MeSH-major] Paget Disease, Extramammary / pathology. Paget Disease, Extramammary / secondary. Urothelium / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma / pathology. Female. Humans. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15717759.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Bao Y, Yoshida D, Morimoto D, Teramoto A: Expression of laminin beta2: a novel marker of hypoxia in pituitary adenomas. Endocr Pathol; 2006;17(3):251-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some studies indicate that pituitary adenoma tissues are hypovascular and have lower oxygen saturation relative to the normal pituitary gland and suggest that this may induce hypoxia.
  • The expression of laminin beta chains was investigated by fluorescent immunohistochemistry of paraffin-embedded sections of tissue from pituitary adenomas of 42 cases (30 cases without apoplexy and 12 with apoplexy) categorized according to Knosp grading and tumor size.
  • We found that only laminin beta2 expression correlated significantly with tumor size, but did not correlate with apoplexy and invasiveness.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / analysis. Cell Hypoxia / physiology. Laminin / biosynthesis. Pituitary Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Blotting, Western. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):471-8 [12904990.001]
  • [Cites] J Anat. 1998 Jul;193 ( Pt 1):1-21 [9758133.001]
  • [Cites] Acta Neurochir (Wien). 1988;92(1-4):93-9 [3407479.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):115-21 [16199896.001]
  • [Cites] Br J Radiol. 2003;76 Spec No 1:S11-22 [15456710.001]
  • [Cites] Endocr Pathol. 2004 Spring;15(1):17-27 [15067173.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 8):36-41 [11395851.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] Surg Neurol. 2000 Mar;53(3):211-9 [10773251.001]
  • [Cites] Endocr J. 2000 Mar;47 Suppl:S77-9 [10890190.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5596-601 [10554040.001]
  • [Cites] Arq Neuropsiquiatr. 1999 Mar;57(1):74-7 [10347728.001]
  • [Cites] Semin Cancer Biol. 2002 Jun;12(3):197-207 [12083850.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 8):29-35 [11395850.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):123-31 [16199897.001]
  • [Cites] Surg Neurol. 1982 Sep;18(3):181-9 [7179072.001]
  • [Cites] Surg Neurol. 2003 May;59(5):386-90; discussion 390-1 [12765811.001]
  • [Cites] Brain Tumor Pathol. 2002;19(1):23-9 [12455885.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):266-76 [11181773.001]
  • [Cites] Neurosurgery. 2005;56(1):65-72; discussion 72-3 [15617587.001]
  • [Cites] J Clin Endocrinol Metab. 1995 May;80(5):1733-8 [7745027.001]
  • [Cites] J Neurosurg. 2003 May;98(5):1084-93 [12744370.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):217-25 [16779673.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):201-9 [11564896.001]
  • [Cites] Onkologie. 2004 Feb;27(1):83-90 [15007254.001]
  • [Cites] Oncologist. 2004;9 Suppl 5:4-9 [15591417.001]
  • [Cites] J Neurosurg. 1986 Mar;64(3):402-7 [3950720.001]
  • [Cites] J Endocrinol Invest. 2003 Jan;26(1):23-8 [12602530.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2379-92 [16369494.001]
  • [Cites] Semin Cell Dev Biol. 2005 Aug-Oct;16(4-5):539-46 [16144691.001]
  • [Cites] Int J Cancer. 1998 Mar 30;76(1):63-72 [9533763.001]
  • [Cites] Exp Cell Res. 2005 Oct 15;310(1):176-85 [16112111.001]
  • [Cites] Acta Neurochir (Wien). 2004 Dec;146(12):1323-7; discussion 1327-8 [15480830.001]
  • [Cites] Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8 [8232800.001]
  • [Cites] Clin Exp Metastasis. 2003;20(3):237-50 [12741682.001]
  • [Cites] Neurosurgery. 2003 Oct;53(4):880-5; discussion 885-6 [14519220.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Aug;51(2):181-8 [10468988.001]
  • (PMID = 17308362.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Laminin; 124148-86-3 / laminin beta2
  •  go-up   go-down


50. Huang J, Wu C, di Sant'Agnese PA, Yao JL, Cheng L, Na Y: Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Anal Quant Cytol Histol; 2007 Jun;29(3):128-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign prostate contains luminal epithelial cells, basal cells and a minor component of neuroendocrine cells whose function may be to regulate the growth, differentiation and secretory function of the prostate gland.
  • Instead, these cells may be enriched after the therapy and they may establish paracrine networks to stimulate androgen-independent proliferation of PC, leading to tumor recurrence.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672372.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


51. Miyamoto S, Maeda Y, Hishima T, Sasaki T: [Case of higher efficacy by chemoradiotherapy for anal canal cancer from left cervix metastases to lymph nodes]. Gan To Kagaku Ryoho; 2009 Feb;36(2):329-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of higher efficacy by chemoradiotherapy for anal canal cancer from left cervix metastases to lymph nodes].
  • She noticed a left neck tumor and had a checkup by a nearby doctor.
  • In examination, the anal region had phyma in a rectal examination, and biopsy revealed it to be a squamous cell carcinoma.
  • For anal canal cancer cStage IV, we performed chemotherapies of S-1+CDDP and local radiotherapy.
  • There was a contraction of a lymph gland, and CT four months later lower endoscopy did not show the apparent phyma.
  • We have continued chemotherapies in an outpatient department sequentially, but the image shows no increase of lymph gland nor increase of the primary tumor for 20 months with no decrease in QOL of the patient.
  • Chemoradiotherapy including S-1 was effective for this case of anal canal cancer distant metastasis for which no apparent cause has been established thus far.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / blood. Colonoscopy. Female. Humans. Lymphatic Metastasis / pathology. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223758.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


52. España L, Martín B, Aragüés R, Chiva C, Oliva B, Andreu D, Sierra A: Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis. Am J Pathol; 2005 Oct;167(4):1125-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 435/Bcl-x(L) or 435/Neo human breast cancer cells were injected into the inguinal mammary gland of nude mice, and tumors, metastases in lymph node, lung, and bone, and bloodstream surviving cells were examined.
  • In conclusion, Bcl-x(L) mediates a phenotype in which redox pathways and glycolysis are coupled to protect breast cancer metastatic cells during transit from the primary tumor to the metastatic state.
  • [MeSH-major] Breast Neoplasms / blood. Breast Neoplasms / metabolism. Carcinoma / blood. Carcinoma / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Bone Neoplasms / genetics. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Bone and Bones. Cell Line, Tumor. Cell Survival. Computational Biology. Electrophoresis, Gel, Two-Dimensional. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Lung. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Lymph Nodes. Lymphatic Metastasis / genetics. Lymphatic Metastasis / pathology. Mass Spectrometry. Mice. Mice, Nude. Models, Biological. Neoplasm Metastasis / genetics. Neoplasm Transplantation. Organ Specificity. Peptide Mapping. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Res. 2003 Jul;1(9):682-9 [12861054.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4285-8 [10200254.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D449-51 [14681454.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 [14665696.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):11-22 [14708024.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):931-43 [14737123.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12589-94 [10535966.001]
  • [Cites] Nature. 1999 Nov 4;402(6757):86-90 [10573422.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):142-50 [10638981.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Mol Med Today. 2000 Apr;6(4):149-56 [10740253.001]
  • [Cites] Cell Death Differ. 2000 Apr;7(4):350-9 [10773819.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):311-8 [10917544.001]
  • [Cites] Cancer. 2000 Oct 25;90(5):286-91 [11038425.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):76-80 [11196201.001]
  • [Cites] Lab Invest. 2001 May;81(5):725-34 [11351044.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Breast Cancer Res Treat. 2001 Sep;69(1):39-51 [11759827.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(1):94-104 [11739725.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6649-54 [12011429.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19396-401 [11904290.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22718-24 [11956188.001]
  • [Cites] Curr Biol. 2002 Jun 25;12(12):1034-9 [12123579.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9830-5 [12118121.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):823 [12192390.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7611-8 [12400004.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):10-1 [12509774.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):258-61 [12519996.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):9-15 [12559171.001]
  • [Cites] Science. 2003 Apr 25;300(5619):650-3 [12714747.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):558-65 [12808061.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42 [12808139.001]
  • [Cites] Cell. 2003 Jun 27;113(7):821-3 [12837240.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):332-7 [15029198.001]
  • [Cites] EMBO J. 2004 Apr 21;23(8):1889-99 [15071501.001]
  • [Cites] Genome Res. 2004 Jun;14(6):1107-18 [15173116.001]
  • [Cites] Breast Cancer Res Treat. 2004 Sep;87(1):33-44 [15377849.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1829-33 [8446596.001]
  • [Cites] J Biol Chem. 1993 Aug 15;268(23):17010-7 [8394326.001]
  • [Cites] Nat Med. 1995 Feb;1(2):149-53 [7585012.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Cancer J Sci Am. 1997 Jul-Aug;3(4):230-7 [9263629.001]
  • [Cites] Trends Biochem Sci. 1998 Sep;23(9):324-8 [9787636.001]
  • [Cites] J Pathol. 1999 Jan;187(1):91-4 [10341709.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 [10430922.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):16-22 [15598930.001]
  • [Cites] Am J Pathol. 2005 May;166(5):1565-79 [15855655.001]
  • [Cites] Adv Cancer Res. 2000;78:31-101 [10547668.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):80-5 [9890174.001]
  • [Cites] J Mass Spectrom. 1999 Feb;34(2):105-16 [10093212.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3808-14 [14506175.001]
  • (PMID = 16192647.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1603674
  •  go-up   go-down


53. Sarathchandra SK, Lunn JA, Hunt GB: Ligation of the caudal mesenteric artery during resection and anastomosis of the colorectal junction for annular adenocarcinoma in two dogs. Aust Vet J; 2009 Sep;87(9):356-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The dogs were euthanased 8 and 10 months, respectively, after surgery because of clinical signs relating to metastatic disease.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Gland Neoplasms / surgery. Dog Diseases / surgery. Mesenteric Arteries / surgery
  • [MeSH-minor] Anastomosis, Surgical / veterinary. Animals. Dogs. Female. Ligation / veterinary. Neoplasm Metastasis. Treatment Outcome

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19703136.001).
  • [ISSN] 1751-0813
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 16
  •  go-up   go-down


54. Polton G: Anal sac gland carcinoma in cocker spaniels. Vet Rec; 2007 Feb 17;160(7):244
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac gland carcinoma in cocker spaniels.
  • [MeSH-major] Anal Gland Neoplasms / genetics. Carcinoma / veterinary. Dog Diseases / genetics
  • [MeSH-minor] Anal Sacs / pathology. Animals. Dogs. Genetic Predisposition to Disease. Pedigree

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17308030.001).
  • [ISSN] 0042-4900
  • [Journal-full-title] The Veterinary record
  • [ISO-abbreviation] Vet. Rec.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


55. Simeonov R, Simeonova G: Computer-assisted nuclear morphometry in the cytological evaluation of canine perianal adenocarcinomas. J Comp Pathol; 2008 Nov;139(4):226-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-assisted nuclear morphometry in the cytological evaluation of canine perianal adenocarcinomas.
  • Stained cytological specimens from 18 canine perianal adenocarcinomas were analyzed by computer-assisted nuclear morphometry in order to evaluate the prognostic value of this technique.
  • These results indicate that MNA, MNP, D max and D min may be used as prognostic indicators for canine perianal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / veterinary. Anal Gland Neoplasms / pathology. Cell Nucleus / ultrastructure. Diagnosis, Computer-Assisted / methods. Dog Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18822421.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Harris AT, Garg M, Yang XB, Fisher SE, Kirkham J, Smith DA, Martin-Hirsch DP, High AS: Raman spectroscopy and advanced mathematical modelling in the discrimination of human thyroid cell lines. Head Neck Oncol; 2009;1:38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Neural Networks (Computer). Spectrum Analysis, Raman / methods. Thyroid Gland / cytology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):396-402 [12612529.001]
  • [Cites] Phys Med Biol. 2000 Feb;45(2):R1-59 [10701500.001]
  • [Cites] Appl Environ Microbiol. 2001 Apr;67(4):1461-9 [11282591.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1756-63 [11037840.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2723-8 [17724716.001]
  • [Cites] Anal Chem. 2000 Jan 1;72(1):12-9 [10655628.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):106-8 [12838309.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):69-90 [12946479.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):1047-52 [14601068.001]
  • [Cites] BJU Int. 2004 Jun;93(9):1232-6 [15180613.001]
  • [Cites] Appl Spectrosc. 2004 Sep;58(9):1128-35 [15479531.001]
  • [Cites] Br J Cancer. 1989 Dec;60(6):897-903 [2557880.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1369-71 [1737400.001]
  • [Cites] Clin Microbiol Infect. 2005 May;11(5):353-8 [15819860.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2166-70 [15928665.001]
  • [Cites] Anal Chem. 2005 Dec 15;77(24):7958-65 [16351143.001]
  • [Cites] Virol J. 2006;3:51 [16805914.001]
  • [Cites] J Surg Oncol. 2006 Dec 15;94(8):725-36 [17131397.001]
  • [Cites] Anal Bioanal Chem. 2007 Mar;387(5):1657-68 [17123068.001]
  • [Cites] Lasers Surg Med. 2003;32(3):210-4 [12605428.001]
  • (PMID = 19863815.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2775737
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


57. Kim JB, Urban K, Cochran E, Lee S, Ang A, Rice B, Bata A, Campbell K, Coffee R, Gorodinsky A, Lu Z, Zhou H, Kishimoto TK, Lassota P: Non-invasive detection of a small number of bioluminescent cancer cells in vivo. PLoS One; 2010;5(2):e9364
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early detection of tumors can significantly improve the outcome of tumor treatment.
  • The resulting single cell clones of the mouse mammary gland tumor (4T1-luc2) showed stable light emission in the range of 10,000 photons/sec/cell.
  • In addition, we showed that only few cells are needed to develop tumors in these mice and tumor progression can be monitored right after the cells are implanted.
  • [MeSH-major] Diagnostic Imaging / methods. Luciferases / metabolism. Luminescent Measurements / methods. Mammary Neoplasms, Experimental / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Genetic Vectors / genetics. Lentivirus / genetics. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Neoplasms / genetics. Neoplasms / metabolism. Neoplasms / pathology. Sensitivity and Specificity. Time Factors. Transfection. Tumor Burden

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6116-24 [18829490.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14342-6 [18794521.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):5-22 [11205917.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12227-32 [11035804.001]
  • [Cites] Mol Ther. 2004 Sep;10(3):545-52 [15336654.001]
  • [Cites] Mol Ther. 2001 Mar;3(3):319-22 [11273773.001]
  • [Cites] Gene Ther. 2001 Oct;8(20):1539-46 [11704814.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 27;100(11):6706-11 [12754375.001]
  • [Cites] Anal Bioanal Chem. 2003 Nov;377(5):826-33 [12879192.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):221-6 [14688412.001]
  • [Cites] Clin Exp Metastasis. 2003;20(8):733-44 [14713107.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] Prostate. 2004 May 15;59(3):292-303 [15042605.001]
  • [Cites] Mol Imaging. 2004 Jan;3(1):9-23 [15142408.001]
  • [Cites] Nat Med. 2004 Jun;10(6):643-8 [15122251.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] Nat Med. 1995 Feb;1(2):149-53 [7585012.001]
  • [Cites] Nucleic Acids Res. 1996 May 1;24(9):1787-8 [8650001.001]
  • [Cites] Nat Biotechnol. 1997 Sep;15(9):871-5 [9306402.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(3):279-84 [10352881.001]
  • [Cites] Nat Med. 2004 Nov;10(11):1257-60 [15502845.001]
  • [Cites] Oncology. 2006;70(6):418-26 [17245103.001]
  • [Cites] J Biomed Opt. 2007 Mar-Apr;12(2):024007 [17477722.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2153-61 [17583576.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Feb;134(2):137-46 [17622558.001]
  • [Cites] PLoS One. 2008;3(6):e2428 [18560594.001]
  • [Cites] Mol Ther. 2008 Sep;16(9):1594-601 [18578010.001]
  • [Cites] BMC Cancer. 2008;8:228 [18691423.001]
  • [Cites] Mol Ther. 2008 Nov;16(11):1848-56 [18766175.001]
  • (PMID = 20186331.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2826408
  •  go-up   go-down


58. Gizard F, Robillard R, Barbier O, Quatannens B, Faucompré A, Révillion F, Peyrat JP, Staels B, Hum DW: TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1. Mol Cell Biol; 2005 Jun;25(11):4335-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, in different breast tumor cell lines, endogenous TReP-132 expression was positively related with a lower proliferation rate.
  • Finally, a statistic profiling of human breast tumor samples highlighted that expression of TReP-132 is correlated with p21 and p27 levels and is associated with lower tumor incidence and aggressiveness.
  • [MeSH-major] Cell Cycle / physiology. Cell Cycle Proteins / genetics. DNA-Binding Proteins / physiology. Sp1 Transcription Factor / metabolism. Transcription Factors / physiology. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Cell Proliferation. Cyclin-Dependent Kinase Inhibitor p21. Cyclin-Dependent Kinase Inhibitor p27. Female. Gene Expression Regulation. Gene Silencing. HeLa Cells. Humans. Promoter Regions, Genetic. RNA, Messenger / analysis. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. Steroidogenic Factor 1